Mark Routbort, M.D., Ph.D.

Peer-Reviewed Articles

1. Hong, L, Di Federico, A, Liu, B, Cooper, AJ, Alessi, JV, Clark, P, Rinsurongkawong, W, Young, C, Li, H, Qin, K, Aminu, M, Santo, V, Elamin, YY, Sepesi, B, Lewis, J, Gibbons, DL, Vaporciyan, AA, Lee, JJ, Le, X, Wu, J, Roy Chowdhuri, S, Routbort, MJ, Futreal, PA, Heymach, JV, Awad, MM, Schoenfeld, AJ, Zhang, J, Ricciuti, B, Deng, L, Vokes, N. Distinct Clinicogenomic Features and Immunotherapy Associations in Pulmonary Sarcomatoid Carcinoma. Journal of Thoracic Oncology 20(12):1763-1777, 2025. e-Pub 2025. PMID: 40716572.
2. Seldomridge AN, White MG, Scally C, Royal RE, Routbort M, Iorgulescu J, Overman MJ, Lee SM, Foo WC, Taggart MW, Song Y, Mansfield PF, Fournier KF, Shen JP, Helmink BA. Clinicopathologic and Molecular Characteristics of High-Grade Appendiceal Mucinous Neoplasms. Ann Surg Oncol, 2025. e-Pub 2025. PMID: 41225239.
3. Ok, CY, Tang, G, Loghavi, S, Hu, S, Wei, Q, Quesada, AE, Routbort, MJ, Kanagal Shamanna, R, Yin, CC, Sarami, I, Garces, S, Agarwal, N, Luthra, R, Fang, H, Jelloul, FZ, Bryan, J, Medeiros, LJ, Patel, KP, Toruner, GA. Comparative Analysis of Targeted RNA-Seq and Optical Genome Mapping for Detecting Gene Rearrangements in Acute Leukemia. Cancers 17(21), 2025. e-Pub 2025. PMID: 41228256.
4. Nirmalanantham, P, Quesada, AE, Ghosh, A, Lin, P, Ok, CY, Yang, RK, Fang, H, Garces, S, Kanagal Shamanna, R, Loghavi, S, Routbort, MJ, Yin, CC, Wei, W, Pasyar, S, Bassett Jr, R, El Hussein, S, Jain, N, Burger, JA, Wierda, WG, Wang, S, Bueso-Ramos, CE, Patel, KP, Medeiros, LJ, Jelloul, FZ. Mutational Landscape and Clinical Impact of SPEN Mutations in Patients with Chronic Lymphocytic Leukemia. Cancers 17(21), 2025. e-Pub 2025. PMID: 41228377.
5. Gouda, M, Janku, F, Yuan, Y, Drusbosky, L, Chen, A, Zheng, X, Patel, KP, Hamilton, SR, Routbort, MJ, Tricoli, JV, Williams, PM, Iafrate, AJ, Sklar, J, Coffey, B, Little, R, Arteaga, CL, O'Dwyer, PJ, Flaherty, KT, Harris, LN, Meric-Bernstam, F. Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131). Clinical Cancer Research 31(20):4299-4310, 2025. e-Pub 2025. PMID: 40388547.
6. Short NJ, Loghavi S, Yilmaz M, Karrar O, Kim K, Dinardo CD, Kadia TM, Maroun M, Borthakur G, Issa GC, Jabbour J, Oran B, Shpall EJ, Popat U, Patel KP, Routbort M, Konopleva M, Ravandi F, Kantarjian H, Daver N. Long-term outcomes in FLT3-mutated acute myeloid leukemia after frontline hypomethylating agent, venetoclax and a FLT3 inhibitor. Haematologica, 2025. e-Pub 2025. PMID: 41035402.
7. Scollon S, Plon SE, Joffe S, Biegel JA, Kulkarni S, Miles G, Patton DR, Coffey B, Winter CL, Tsongalis GJ, Routbort MJ, Ramirez NC, Saguilig L, Piao J, Alonzo TA, Berg SL, Fox E, Weigel B, Hawkins DS, Abrams JS, Mooney M, Takebe N, Tricoli JV, Janeway KA, Seibel NL, Parsons DW. Germline Cancer Predisposition Results From the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial. JCO Precis Oncol 9:e2500742, 2025. e-Pub 2025. PMID: 41166674.
8. Wang, P, Yang, RK, Jelloul, FZ, Luthra, R, Routbort, MJ, Chen, H, Loghavi, S, Ok, CY, Kanagal Shamanna, R, Roy Chowdhuri, S, Medeiros, LJ, Patel, KP. Routine Clinical Liquid Biopsy Testing for Solid Tumors Delivers the Promise of Minimally Invasive Detection of Genomic Variants With a Faster Turnaround Time. JCO Precision Oncology 9, 2025. e-Pub 2025. PMID: 40138600.
9. Marczyk, VR, Fazeli, S, Dadu, R, Busaidy, NL, Iyer, PC, Hu, MI, Sherman, SI, Hamidi, S, Hosseini, SM, Williams, MD, Ahmed, S, Routbort, MJ, Luthra, R, Roy Chowdhuri, S, San Lucas, FA, Patel, KP, Hong, DS, Zafereo, M, Wang, RJ, Maniakas, A, Waguespack, SG, Cabanillas, ME. NTRK Fusion-Positive Thyroid Carcinoma. JCO Precision Oncology 9, 2025. e-Pub 2025. PMID: 39983078.
10. Yang RK, Alvarez H, Lucas AS, Roy-Chowdhuri S, Rashid A, Chen H, Ballester LY, Sweeney K, Routbort MJ, Patel KP, Luthra R, Medeiros LJ, Toruner GA. Microsatellite instability and high tumor mutational burden detected by next generation sequencing are concordant with loss of mismatch repair proteins by immunohistochemistry. Cancer Genet 290-291:44-50, 2025. e-Pub 2025. PMID: 39700818.
11. Holla, V, Kahle, M, Kim, SH, Ronaghy, A, Yang, RK, Patel, KP, Routbort, MJ, Overman, MJ, Ileana Dumbrava, EE, Mills Shaw, KR, Karp, DD, Meric-Bernstam, F. Genomic Alterations in DNA Mismatch Repair Genes Across Different Cancer Types. JCO Precision Oncology 8, 2024. e-Pub 2024. PMID: 39576951.
12. Pan, K, Owens, J, Elamin, YY, Lu, C, Routbort, MJ, Zhang, J, Fossella, FV, Vailati Negrao, M, Altan, M, Pozadzides, JV, Skoulidis, F, Tsao, A, Cascone, T, Heymach, JV, Ostrin, EJ, Le, X. Mutational Characteristics and Clinical Outcomes for Lung Adenocarcinoma With EGFR Germline Mutations. Journal of Thoracic Oncology 19(10):1438-1448, 2024. e-Pub 2024. PMID: 38866326.
13. Loghavi, S, Wei, Q, Ravandi-Kashani, F, Quesada, AE, Routbort, MJ, Hu, S, Toruner, GA, Wang, S, Wang, W, Miranda, R, Li, S, Xu, J, DiNardo, C, Daver, N, Kadia, TM, Issa, GC, Kantarjian, HM, Medeiros, LJ, Tang, G. Optical genome mapping improves the accuracy of classification, risk stratification, and personalized treatment strategies for patients with acute myeloid leukemia. American journal of hematology 99(10):1959-1968, 2024. e-Pub 2024. PMID: 39016111.
14. Yin, CC, Tam, W, Walker, SM, Kaur, A, Ouseph, MM, Xie, W, Weinberg, OK, Li, P, Zuo, Z, Routbort, MJ, Chen, S, Medeiros, LJ, George, T, Orazi, A, Arber, DA, Bagg, A, Hasserjian, RP, Wang, S. STAT5B mutations in myeloid neoplasms differ by disease subtypes but characterize a subset of chronic myeloid neoplasms with eosinophilia and/or basophilia. Haematologica 109(6):1825-1826, 2024. e-Pub 2024. PMID: 37981812.
15. Diks, J, Tang, Z, Altan, M, Anderson, S, Chen, H, Rashid, A, Yang, RK, Routbort, MJ, Patel, KP, Toruner, GA, Medeiros, LJ, Tang, G, Luthra, R, Roy Chowdhuri, S. Detection of clinically actionable gene fusions by next-generation sequencing-based RNA sequencing of non–small cell lung cancer cytology specimens. Cancer Cytopathology 132(1):41-49, 2024. e-Pub 2024. PMID: 37747438.
16. Zheng, L, Luthra, R, Alvarez, HA, San Lucas, FA, Duose, D, Wistuba, II, Fuller, GN, Ballester, L, Roy Chowdhuri, S, Sweeney, K, Rashid, A, Yang, RK, Chen, W, Liu, A, Wu, Y, Albarracin, C, Patel, KP, Routbort, MJ, Sahin, AA, Ding, Q, Chen, H. Intragenic EGFR::EGFR.E1E8 Fusion (EGFRvIII) in 4331 Solid Tumors. Cancers 16(1), 2024. e-Pub 2024. PMID: 38201434.
17. Hong, L, Aminu, M, Li, S, Lu, X, Petranovic, M, Saad, MB, Chen, P, Qin, K, Varghese, S, Rinsurongkawong, W, Rinsurongkawong, V, Spelman, AR, Elamin, YY, Vailati Negrao, M, Skoulidis, F, Gay, CM, Cascone, T, Gandhi, S, Lin, SH, Lee, PP, Carter, B, Wu, CC, Antonoff, MB, Sepesi, B, Lewis, J, Gibbons, DL, Vaporciyan, AA, Le, X, Lee, JJ, Roy Chowdhuri, S, Routbort, MJ, Gainor, J, Heymach, JV, Lou, Y, Wu, J, Zhang, J, Vokes, N. Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer. Nature communications 14(1), 2023. e-Pub 2023. PMID: 36755027.
18. Chen H, Ding Q, Khazai L, Zhao L, Damodaran S, Litton JK, Rauch GM, Yam C, Chang JT, Seth S, Lim B, Thompson AM, Mittendorf EA, Adrada B, Virani K, White JB, Ravenberg E, Song X, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim N, Routbort MJ, Sahin A, Valero V, Symmans WF, Tripathy D, Wang WL, Moulder S, Huo L. PTEN in triple-negative breast carcinoma: protein expression and genomic alteration in pretreatment and posttreatment specimens. Ther Adv Med Oncol 15:17588359231189422, 2023. e-Pub 2023. PMID: 37547448.
19. O’Dwyer, PJ, Gray, R, Flaherty, KT, Chen, A, Li, S, Wang, V, McShane, LM, Patton, DR, Tricoli, JV, Williams, PM, Iafrate, AJ, Sklar, J, Mitchell, E, Takebe, N, Sims, DJ, Coffey, B, Fu, T, Routbort, MJ, Rubinstein, L, Little, R, Arteaga, CL, Marinucci, D, Hamilton, SR, Conley, BA, Harris, LN, Doroshow, JH. The NCI-MATCH trial. Nature medicine 29(6):1349-1357, 2023. e-Pub 2023. PMID: 37322121.
20. Zuo, Z, Medeiros, LJ, Garces, S, Routbort, MJ, Ok, CY, Loghavi, S, Kanagal Shamanna, R, Jelloul, FZ, Garcia-Manero, G, Chien, KS, Patel, KP, Luthra, R, Yin, CC. Concurrent Mutations in SF3B1 and PHF6 in Myeloid Neoplasms. Biology 12(1), 2023. e-Pub 2023. PMID: 36671709.
21. Tashakori M, Khoury JD, Routbort MJ, Patel KP, Wang SA, Ok CY, El-Hussein S, Kanagal-Shamanna R, Luthra R, Hu S, Lin P, Pemmaraju N, Bose P, Verstovsek S, Bueso-Ramos CE, Medeiros LJ, Loghavi S. Clinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations. Mod Pathol 35(11):1677-1683, 2022. e-Pub 2022. PMID: 35690645.
22. Yang RK, Chen H, Roy-Chowdhuri S, Rashid A, Alvarez H, Routbort M, Patel KP, Luthra R, Medeiros LJ, Toruner GA. Clinical Testing for Mismatch Repair in Neoplasms Using Multiple Laboratory Methods. Cancers (Basel) 14(19), 2022. e-Pub 2022. PMID: 36230473.
23. Sakhdari A, Class C, Montalban-Bravo G, Sasaki K, Bueso-Ramos CE, Patel KP, Routbort MJ, Loghavi S, Ok CY, Quesada A, Khoury JD, Konoplev SN, Kantarjian HP, Garcia-Manero G, Medeiros LJ, Kanagal-Shamanna R. Immunohistochemical loss of enhancer of Zeste Homolog 2 (EZH2) protein expression correlates with EZH2 alterations and portends a worse outcome in myelodysplastic syndromes. Mod Pathol 35(9):1212-1219, 2022. e-Pub 2022. PMID: 35504958.
24. Zaleski MP, Chen H, Roy-Chowdhuri S, Patel KP, Luthra R, Routbort MJ, Kamat AM, Gao J, Siefker-Radtke A, Czerniak B, Guo CC. Distinct Gene Mutations Are Associated With Clinicopathologic Features in Urachal Carcinoma. Am J Clin Pathol 158(2):263-269, 2022. e-Pub 2022. PMID: 35467000.
25. Wang JR, Montierth M, Xu L, Goswami M, Zhao X, Cote G, Wang W, Iyer P, Dadu R, Busaidy NL, Lai SY, Gross ND, Ferrarotto R, Lu C, Gunn GB, Williams MD, Routbort M, Zafereo ME, Cabanillas ME. Impact of Somatic Mutations on Survival Outcomes in Patients With Anaplastic Thyroid Carcinoma. JCO Precis Oncol 6:e2100504, 2022. e-Pub 2022. PMID: 35977347.
26. Elamin YY, Robichaux JP, Carter BW, Altan M, Tran H, Gibbons DL, Heeke S, Fossella FV, Lam VK, Le X, Negrao MV, Nilsson MB, Patel A, Vijayan RSK, Cross JB, Zhang J, Byers LA, Lu C, Cascone T, Feng L, Luthra R, San Lucas FA, Mantha G, Routbort M, Blumenschein G, Tsao AS, Heymach JV. Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity. Cancer Cell 40(7):754-767.e6, 2022. e-Pub 2022. PMID: 35820397.
27. Parsons DW, Janeway KA, Patton DR, Winter CL, Coffey B, Williams PM, Roy-Chowdhuri S, Tsongalis GJ, Routbort M, Ramirez NC, Saguilig L, Piao J, Alonzo TA, Berg SL, Fox E, Hawkins DS, Abrams JS, Mooney M, Takebe N, Tricoli JV, Seibel NL, MATCH Team NP. Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial. J Clin Oncol 40(20):2224-2234, 2022. e-Pub 2022. PMID: 35353553.
28. Tashakori M, Kadia T, Loghavi S, Daver N, Kanagal-Shamanna R, Pierce S, Sui D, Wei P, Khodakarami F, Tang Z, Routbort M, Bivins CA, Jabbour EJ, Medeiros LJ, Bhalla K, Kantarjian HM, Ravandi F, Khoury JD. TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia. Blood 140(1):58-72, 2022. e-Pub 2022. PMID: 35390143.
29. Jelloul FZ, Yang R, Garces S, Kanagal-Shamanna R, Ok CY, Loghavi S, Routbort MJ, Zuo Z, Yin CC, Floyd K, Bassett RL, Wierda W, Jain N, Thompson P, Luthra R, Medeiros LJ, Patel KP. Landscape of NOTCH1 mutations and co-occurring biomarker alterations in chronic lymphocytic leukemia. Leuk Res 116:106827, 2022. e-Pub 2022. PMID: 35430388.
30. Kanagal-Shamanna R, Orazi A, Hasserjian RP, Arber DA, Reichard K, Hsi ED, Bagg A, Rogers HJ, Geyer J, Darbaniyan F, Do KA, Devins KM, Pozdnyakova O, George TI, Cin PD, Greipp PT, Routbort MJ, Patel K, Garcia-Manero G, Verstovsek S, Medeiros LJ, Wang SA, Bueso-Ramos C. Myelodysplastic/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology Group. Mod Pathol 35(4):470-479, 2022. e-Pub 2022. PMID: 34775472.
31. El Hussein S, DiNardo CD, Takahashi K, Khoury JD, Fang H, Furudate K, Lyapichev KA, Garces S, Kanagal-Shamanna R, Ok CY, Patel KP, Routbort MJ, Ravandi F, Medeiros LJ, Wang SA, Loghavi S. Acquired WT1 mutations contribute to relapse of NPM1-mutated acute myeloid leukemia following allogeneic hematopoietic stem cell transplant. Bone Marrow Transplant 57(3):370-376, 2022. e-Pub 2022. PMID: 34992253.
32. Jelloul FZ, Yang RK, Wang P, Garces S, Kanagal-Shamanna R, Ok CY, Loghavi S, Routbort MJ, Zuo Z, Yin CC, Floyd K, Bassett RL, Wierda WG, Jain N, Thompson PA, Luthra R, Medeiros LJ, Patel KP. Non-coding NOTCH1 mutations in chronic lymphocytic leukemia negatively impact prognosis. Am J Hematol 97(3):E100-E102, 2022. e-Pub 2022. PMID: 34989420.
33. Ramani NS, Patel KP, Routbort MJ, Alvarez H, Broaddus R, Chen H, Rashid A, Lazar A, San Lucas FA, Yao H, Manekia J, Dang H, Barkoh BA, Medeiros LJ, Luthra R, Roy-Chowdhuri S. Factors Impacting Clinically Relevant RNA Fusion Assays Using Next-Generation Sequencing. Arch Pathol Lab Med 145(11):1405-1412, 2021. e-Pub 2021. PMID: 33493304.
34. Kanagal-Shamanna R, Montalban-Bravo G, Sasaki K, Darbaniyan F, Jabbour E, Bueso-Ramos C, Wei Y, Chien K, Kadia T, Ravandi F, Borthakur G, Soltysiak KA, Routbort M, Patel K, Pierce S, Medeiros LJ, Kantarjian HM, Garcia-Manero G. Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes. Cancer 127(19):3552-3565, 2021. e-Pub 2021. PMID: 34161603.
35. Zhang BM, Keegan A, Li P, Lindeman NI, Nagarajan R, Routbort MJ, Vasalos P, Kim AS, Merker JD. An Overview of Characteristics of Clinical Next-Generation Sequencing-Based Testing for Hematologic Malignancies. Arch Pathol Lab Med 145(9):1110-1116, 2021. e-Pub 2021. PMID: 33450747.
36. Ramani NS, Chen H, Broaddus RR, Lazar AJ, Luthra R, Medeiros LJ, Patel KP, Rashid A, Routbort MJ, Stewart J, Tang Z, Bassett R, Manekia J, Barkoh BA, Dang H, Roy-Chowdhuri S. Utilization of cytology smears improves success rates of RNA-based next-generation sequencing gene fusion assays for clinically relevant predictive biomarkers. Cancer Cytopathol 129(5):374-382, 2021. e-Pub 2021. PMID: 33119213.
37. Kanagal-Shamanna R, Montalban-Bravo G, Katsonis P, Sasaki K, Class CA, Jabbour E, Sallman D, Hunter AM, Benton C, Chien KS, Luthra R, Bueso-Ramos CE, Kadia T, Andreeff M, Komrokji RS, Al Ali NH, Short N, Daver N, Routbort MJ, Khoury JD, Patel K, Ganan-Gomez I, Wei Y, Borthakur G, Ravandi F, Do KA, Soltysiak KA, Lichtarge O, Medeiros LJ, Kantarjian H, Garcia-Manero G. Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis. Blood Cancer J 11(3):52, 2021. e-Pub 2021. PMID: 33677472.
38. Lyapichev KA, Bah I, Huen A, Duvic M, Routbort MJ, Wang W, Jorgensen JL, Medeiros LJ, Vega F, Craig FE, Wang SA. Determination of immunophenotypic aberrancies provides better assessment of peripheral blood involvement by mycosis fungoides/Sézary syndrome than quantification of CD26- or CD7- CD4+ T-cells. Cytometry B Clin Cytom 100(2):183-191, 2021. e-Pub 2021. PMID: 32667737.
39. Morris JS, Luthra R, Liu Y, Duose DY, Lee W, Reddy NG, Windham J, Chen H, Tong Z, Zhang B, Wei W, Ganiraju M, Broom BM, Alvarez HA, Mejia A, Veeranki O, Routbort MJ, Morris VK, Overman MJ, Menter D, Katkhuda R, Wistuba II, Davis JS, Kopetz S, Maru DM. Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting. Clin Cancer Res 27(1):120-130, 2021. e-Pub 2021. PMID: 33109741.
40. DiNardo CD, Beird HC, Estecio M, Hardikar S, Takahashi K, Bannon SA, Borthakur G, Jabbour E, Gumbs C, Khoury JD, Routbort M, Gong T, Kondo K, Kantarjian H, Garcia-Manero G, Chen T, Futreal PA. Germline DNMT3A mutation in familial acute myeloid leukaemia. Epigenetics 16(5):1-10, 2021. e-Pub 2020. PMID: 32856987.
41. Flaherty KT, Gray RJ, Chen AP, Li S, McShane LM, Patton D, Hamilton SR, Williams PM, Iafrate AJ, Sklar J, Mitchell EP, Harris LN, Takebe N, Sims DJ, Coffey B, Fu T, Routbort M, Zwiebel JA, Rubinstein LV, Little RF, Arteaga CL, Comis R, Abrams JS, O'Dwyer PJ, Conley BA, team N. Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH). J Clin Oncol 38(33):3883-3894, 2020. e-Pub 2020. PMID: 33048619.
42. Flaherty KT, Gray R, Chen A, Li S, Patton D, Hamilton SR, Williams PM, Mitchell EP, Iafrate AJ, Sklar J, Harris LN, McShane LM, Rubinstein LV, Sims DJ, Routbort M, Coffey B, Fu T, Zwiebel JA, Little RF, Marinucci D, Catalano R, Magnan R, Kibbe W, Weil C, Tricoli JV, Alexander B, Kumar S, Schwartz GK, Meric-Bernstam F, Lih CJ, McCaskill-Stevens W, Caimi P, Takebe N, Datta V, Arteaga CL, Abrams JS, Comis R, O'Dwyer PJ, Conley BA, Team N. THE MOLECULAR ANALYSIS FOR THERAPY CHOICE (NCI-MATCH) TRIAL: LESSONS for GENOMIC TRIAL DESIGN. J Natl Cancer Inst 112(10):1021-1029, 2020. e-Pub 2020. PMID: 31922567.
43. Gupta SK, Jain N, Tang G, Futreal A, Wang SA, Khoury JD, Yang RK, Fang H, Patel KP, Luthra R, Routbort M, Barkoh BA, Chen W, Mao X, Zhang J, Medeiros LJ, Bueso-Ramos CE, Loghavi S. A Cryptic BCR-PDGFRB Fusion Resulting in a Chronic Myeloid Neoplasm With Monocytosis and Eosinophilia: A Novel Finding With Treatment Implications. J Natl Compr Canc Netw 18(10):1300-1304, 2020. e-Pub 2020. PMID: 33022638.
44. Quesada AE, Montalban-Bravo G, Luthra R, Patel KP, Sasaki K, Bueso-Ramos CE, Khoury JD, Routbort MJ, Bassett R, Hidalgo-Lopez JE, Zhao C, Lin P, Loghavi S, Ok CY, Kadia T, DiNardo CD, Kantarjian H, Garcia-Manero G, Kanagal-Shamanna R. Clinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo acute myeloid leukemia with mutated RUNX1. Mod Pathol 33(9):1678-1689, 2020. e-Pub 2020. PMID: 32238878.
45. Shuai W, Lin P, Strati P, Patel KP, Routbort MJ, Hu S, Wei P, Khoury JD, You MJ, Loghavi S, Tang Z, Fang H, Thakral B, Medeiros LJ, Wang W. Clinicopathological characterization of chronic lymphocytic leukemia with MYD88 mutations: L265P and non-L265P mutations are associated with different features. Blood Cancer J 10(8):86, 2020. e-Pub 2020. PMID: 32848129.
46. Tang Z, Chen H, Hong L, Tang G, Toruner GA, Wang W, Roy Chowdhuri S, Yin W, Jung HS, Gu J, Routbort MJ, Zhang J, Khoury JD, Medeiros LJ. Inconsistent Intersample ALK FISH Results in Patients with Lung Cancer: Analysis of Potential Causes. Cancers (Basel) 12(7):1-17, 2020. e-Pub 2020. PMID: 32674491.
47. Montalban-Bravo G, Kanagal-Shamanna R, Class CA, Sasaki K, Ravandi F, Cortes JE, Daver N, Takahashi K, Short NJ, DiNardo CD, Jabbour E, Borthakur G, Naqvi K, Issa GC, Konopleva M, Khoury JD, Routbort M, Pierce S, Do KA, Bueso-Ramos C, Patel K, Kantarjian H, Garcia-Manero G, Kadia TM. Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy. Am J Hematol 95(6):612-622, 2020. e-Pub 2020. PMID: 32112433.
48. Robichaux JP, Elamin YY, Vijayan RSK, Nilsson MB, Hu L, He J, Zhang F, Pisegna M, Poteete A, Sun H, Li S, Chen T, Han H, Negrao MV, Ahnert JR, Diao L, Wang J, Le X, Meric-Bernstam F, Routbort M, Roeck B, Yang Z, Raymond VM, Lanman RB, Frampton GM, Miller VA, Schrock AB, Albacker LA, Wong KK, Cross JB, Heymach JV. Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity. Cancer Cell 37(3):420, 2020. e-Pub 2020. PMID: 32183953.
49. Yang RK, Qing Y, Jelloul FZ, Routbort MJ, Wang P, Shaw K, Zhang J, Lee J, Medeiros LJ, Kopetz S, Tetzlaff MT, Broaddus RR. Identification of biomarkers of immune checkpoint blockade efficacy in recurrent or refractory solid tumor malignancies. Oncotarget 11(6):600-618, 2020. e-Pub 2020. PMID: 32110280.
50. Abou Dalle I, Kantarjian H, Bannon SA, Kanagal-Shamanna R, Routbort M, Patel KP, Hu S, Bhalla K, Garcia-Manero G, DiNardo CD. Successful lenalidomide treatment in high risk myelodysplastic syndrome with germline DDX41 mutation. Am J Hematol 95(2):227-229, 2020. e-Pub 2019. PMID: 31400013.
51. Sakhdari A, Thakral B, Loghavi S, Kanagal-Shamanna R, Yin CC, Zuo Z, Routbort MJ, Luthra R, Medeiros LJ, Wang SA, Patel KP, Ok CY. RAS and TP53 can predict survival in adults with T-cell lymphoblastic leukemia treated with hyper-CVAD. Cancer Med 9(3):849-858, 2020. e-Pub 2019. PMID: 31804006.
52. Ruiz-Cordero R, Ma J, Khanna A, Lyons G, Rinsurongkawong W, Bassett R, Guo M, Routbort MJ, Zhang J, Skoulidis F, Heymach J, Roarty EB, Tang Z, Medeiros LJ, Patel KP, Luthra R, Roy-Chowdhuri S. Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations. BMC Cancer 20(1):83, 2020. e-Pub 2020. PMID: 32005111.
53. Keegan A, Bridge JA, Lindeman NI, Long TA, Merker JD, Moncur JT, Montgomery ND, Nagarajan R, Rothberg PG, Routbort MJ, Vasalos P, Xian R, Kim AS. Proficiency Testing of Standardized Samples Shows High Interlaboratory Agreement for Clinical Next Generation Sequencing-Based Hematologic Malignancy Assays With Survey Material-Specific Differences in Variant Frequencies. Arch Pathol Lab Med 144(8):959-966, 2020. e-Pub 2020. PMID: 31986076.
54. Chen Z, Ok CY, Wang W, Goswami M, Tang G, Routbort M, Jorgensen JL, Medeiros LJ, Wang SA. Low-Grade Myelodysplastic Syndromes With Preserved CD34+ B-Cell Precursors (CD34+ Hematogones). Cytometry B Clin Cytom 98(1):36-42, 2020. e-Pub 2019. PMID: 31211490.
55. Bannon SA, Routbort MJ, Montalban-Bravo G, Mehta RS, Jelloul FZ, Takahashi K, Daver N, Oran B, Pemmaraju N, Borthakur G, Naqvi K, Issa G, Sasaki K, Alvarado Y, Kadia TM, Konopleva M, Shamanna RK, Khoury JD, Ravandi F, Champlin R, Kantarjian HM, Bhalla K, Garcia-Manero G, Patel KP, DiNardo CD. Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations. Front Oncol 10:582213, 2020. e-Pub 2020. PMID: 33585199.
56. Raghav K, Loree JM, Morris JS, Overman MJ, Yu R, Meric-Bernstam F, Menter D, Korphaisarn K, Kee B, Muranyi A, Singh S, Routbort M, Chen K, Shaw KRM, Katkhuda R, Shanmugam K, Maru D, Fakih M, Kopetz S. Validation of HER2 Amplification as a Predictive Biomarker for Anti-Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal Cancer. JCO Precis Oncol 3:1-13, 2019. e-Pub 2019. PMID: 35100667.
57. Ruiz-Cordero R, Rao P, Li L, Qi Y, Atherton D, Peng B, Singh RR, Kim TB, Kawakami F, Routbort MJ, Alouch N, Chow CB, Tang X, Lu W, Brimo F, Matin SF, Wood CG, Tannir NM, Wistuba II, Chen K, Wang J, Medeiros LJ, Karam JA, Tamboli P, Sircar K. Hybrid oncocytic/chromophobe renal tumors are molecularly distinct from oncocytoma and chromophobe renal cell carcinoma. Mod Pathol 32(11):1698-1707, 2019. e-Pub 2019. PMID: 31231128.
58. Hu B, Patel KP, Chen HC, Wang X, Luthra R, Routbort MJ, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson P, Burger J, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating M, Wierda WG. Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patients. Br J Haematol 187(3):307-318, 2019. e-Pub 2019. PMID: 31243771.
59. Chen Z, Wang SA, Goswami M, Tang G, Routbort MJ, Patel KP, Luthra R, Medeiros LJ, Ok CY. Comparison of therapy-related myelodysplastic syndrome with ring sideroblasts and de novo myelodysplastic syndrome with ring sideroblasts. Leuk Res 86:106227, 2019. e-Pub 2019. PMID: 31557598.
60. Luo X, Feurstein S, Mohan S, Porter CC, Jackson SA, Keel S, Chicka M, Brown AL, Kesserwan C, Agarwal A, Luo M, Li Z, Ross JE, Baliakas P, Pineda-Alvarez D, DiNardo CD, Bertuch AA, Mehta N, Vulliamy T, Wang Y, Nichols KE, Malcovati L, Walsh MF, Rawlings LH, McWeeney SK, Soulier J, Raimbault A, Routbort MJ, Zhang L, Ryan G, Speck NA, Plon SE, Wu D, Godley LA. ClinGen Myeloid Malignancy Variant Curation Expert Panel recommendations for germline RUNX1 variants. Blood Adv 3(20):2962-2979, 2019. e-Pub 2019. PMID: 31648317.
61. Robichaux JP, Elamin YY, Vijayan RSK, Nilsson MB, Hu L, He J, Zhang F, Pisegna M, Poteete A, Sun H, Li S, Chen T, Han H, Negrao MV, Ahnert JR, Diao L, Wang J, Le X, Meric-Bernstam F, Routbort M, Roeck B, Yang Z, Raymond VM, Lanman RB, Frampton GM, Miller VA, Schrock AB, Albacker LA, Wong KK, Cross JB, Heymach JV. Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity. Cancer Cell 36(4):444-457.e7, 2019. e-Pub 2019. PMID: 31588020.
62. Sakhdari A, Ok CY, Patel KP, Kanagal-Shamanna R, Yin CC, Zuo Z, Hu S, Routbort MJ, Luthra R, Medeiros LJ, Khoury JD, Loghavi S. TP53 mutations are common in mantle cell lymphoma, including the indolent leukemic non-nodal variant. Ann Diagn Pathol 41:38-42, 2019. e-Pub 2019. PMID: 31132650.
63. Arango NP, Brusco L, Shaw KRM, Chen K, Eterovic AK, Holla V, Johnson A, Litzenburger B, Khotskaya YB, Sanchez N, Bailey A, Zheng X, Horombe C, Kopetz S, Farhangfar CJ, Routbort M, Broaddus R, Bernstam EV, Mendelsohn J, Mills GB, Meric-Bernstam F. Correction: A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory. Oncotarget 10(50):5254, 2019. e-Pub 2019. PMID: 31497255.
64. Quesada AE, Routbort MJ, DiNardo CD, Bueso-Ramos CE, Kanagal-Shamanna R, Khoury JD, Thakral B, Zuo Z, Yin CC, Loghavi S, Ok CY, Wang SA, Tang Z, Bannon SA, Benton CB, Garcia-Manero G, Kantarjian H, Luthra R, Medeiros LJ, Patel KP. DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease. Am J Hematol 94(7):757-766, 2019. e-Pub 2019. PMID: 30963592.
65. Hu B, Patel KP, Chen HC, Wang X, Wang F, Luthra R, Routbort MJ, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson P, Burger J, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating MJ, Wierda WG. Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments. Br J Haematol 185(5):852-864, 2019. e-Pub 2019. PMID: 30924136.
66. Campbell WS, Carter AB, Cushman-Vokoun AM, Greiner TC, Dash RC, Routbort M, de Baca ME, Campbell JR. A Model Information Management Plan for Molecular Pathology Sequence Data Using Standards: From Sequencer to Electronic Health Record. J Mol Diagn 21(3):408-417, 2019. e-Pub 2019. PMID: 30797065.
67. Merker JD, Devereaux K, Iafrate AJ, Kamel-Reid S, Kim AS, Moncur JT, Montgomery SB, Nagarajan R, Portier BP, Routbort MJ, Smail C, Surrey LF, Vasalos P, Lazar AJ, Lindeman NI. Proficiency Testing of Standardized Samples Shows Very High Interlaboratory Agreement for Clinical Next-Generation Sequencing-Based Oncology Assays. Arch Pathol Lab Med 143(4):463-471, 2019. e-Pub 2019. PMID: 30376374.
68. Genutis LK, Tomsic J, Bundschuh RA, Brock PL, Williams MD, Roychowdhury S, Reeser JW, Frankel WL, Alsomali M, Routbort MJ, Broaddus RR, Wakely PE, Phay JE, Walker CJ, de la Chapelle A. Microsatellite Instability Occurs in a Subset of Follicular Thyroid Cancers. Thyroid 29(4):523-529, 2019. e-Pub 2019. PMID: 30747051.
69. Tetzlaff MT, Curry JL, Ning J, Sagiv O, Kandl TL, Peng B, Bell D, Routbort M, Hudgens CW, Ivan D, Kim TB, Chen K, Eterovic AK, Shaw K, Prieto VG, Yemelyanova A, Esmaeli B. Distinct Biological Types of Ocular Adnexal Sebaceous Carcinoma: HPV-Driven and Virus-Negative Tumors Arise through Nonoverlapping Molecular-Genetic Alterations. Clin Cancer Res 25(4):1280-1290, 2019. e-Pub 2019. PMID: 30420449.
70. Kanagal-Shamanna R, Jain P, Patel KP, Routbort M, Bueso-Ramos C, Alhalouli T, Khoury JD, Luthra R, Ferrajoli A, Keating M, Jain N, Burger J, Estrov Z, Wierda W, Kantarjian HM, Medeiros LJ. Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation. Cancer 125(4):559-574, 2019. e-Pub 2019. PMID: 30508305.
71. Ok CY, Loghavi S, Sui D, Wei P, Kanagal-Shamanna R, Yin CC, Zuo Z, Routbort MJ, Tang G, Tang Z, Jorgensen JL, Luthra R, Ravandi F, Kantarjian HM, DiNardo CD, Medeiros LJ, Wang SA, Patel KP. Persistent IDH1/2 mutation in remission can predict relapse in patients with acute myeloid leukemia. Haematologica 104(2):305-311, 2019. e-Pub 2019. PMID: 30171025.
72. Swaminathan M, Bannon SA, Routbort M, Naqvi K, Kadia TM, Takahashi K, Alvarado Y, Ravandi-Kashani F, Patel KP, Champlin R, Kantarjian H, Strong L, DiNardo CD. Hematologic malignancies and Li-Fraumeni syndrome. Cold Spring Harb Mol Case Stud 5(1), 2019. e-Pub 2019. PMID: 30709875.
73. Patel KP, Ruiz-Cordero R, Chen W, Routbort MJ, Floyd K, Rodriguez S, Galbincea J, Barkoh BA, Hatfield D, Khogeer H, Kanagal-Shamanna R, Yin CC, Zuo Z, Loghavi S, Ok CY, DiNardo CD, Luthra R, Medeiros LJ. Ultra-Rapid Reporting of GENomic Targets (URGENTseq): Clinical Next-Generation Sequencing Results within 48 Hours of Sample Collection. J Mol Diagn 21(1):89-98, 2019. e-Pub 2019. PMID: 30577887.
74. Dumbrava EEI, Balaji K, Raghav K, Hess K, Javle M, Blum-Murphy M, Ajani J, Kopetz S, Broaddus R, Routbort M, Demirhan M, Zheng X, Pant S, Tsimberidou AM, Subbiah V, Hong DS, Rodon J, Shaw KM, Piha-Paul SA, Meric-Bernstam F. Targeting ERBB2 (HER2) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications. JCO Precis Oncol 3, 2019. e-Pub 2019. PMID: 32923865.
75. Abou Dalle I, Bannon SA, Patel KP, Routbort MJ, Cortes JE, Ferrajoli A, Kontoyiannis DP, Wang SA, DiNardo CD. Germline Genetic Predisposition to Myeloid Neoplasia From GATA2 Gene Mutations: Lessons Learned From Two Cases. JCO Precis Oncol 3:1-5, 2019. e-Pub 2019. PMID: 32914014.
76. Dumbrava EI, Brusco L, Daniels M, Wathoo C, Shaw K, Lu K, Zheng X, Strong L, Litton J, Arun B, Eterovic AK, Routbort M, Patel K, Qi Y, Piha-Paul S, Subbiah V, Hong D, Rodon J, Kopetz S, Mendelsohn J, Mills GB, Chen K, Meric-Bernstam F. Expanded analysis of secondary germline findings from matched tumor/normal sequencing identifies additional clinically significant mutations. JCO Precis Oncol 3:1-11, 2019. e-Pub 2019. PMID: 31517177.
77. Garces S, Khoury JD, Kanagal-Shamanna R, Salem A, Wang SA, Ok CY, Hu S, Patel KP, Routbort MJ, Luthra R, Tang G, Schlette EJ, Bueso-Ramos CE, Medeiros LJ, Loghavi S. Chronic lymphocytic leukemia with proliferation centers in bone marrow is associated with younger age at initial presentation, complex karyotype and TP53 disruption. Hum Pathol 82:215-231, 2018. e-Pub 2018. PMID: 30086334.
78. Assi R, Gur HD, Loghavi S, Konoplev SN, Konopleva M, Daver N, Tashakori M, Kadia T, Routbort M, Salem A, Kanagal-Shamanna R, Quesada A, Jabbour EJ, Kornblau SM, Jeffrey Medeiros L, Kantarjian H, Khoury JD. P53 Protein Overexpression in De Novo Acute Myeloid Leukemia Patients with Normal Diploid Karyotype Correlates with FLT3 Internal Tandem Duplication and Worse Relapse-Free Survival. Am J Hematol 93(11):1376-1383, 2018. e-Pub 2018. PMID: 30117185.
79. Chen H, Luthra R, Patel KP, Routbort M, Rashid A, Roy-Chowdhuri S, Lazar A, Broaddus R, Manekia J, Singh RR, Yemelyanova A. Challenges in next generation sequencing analysis of somatic mutations in transplant patients. Cancer Genet 226-227:17-22, 2018. e-Pub 2018. PMID: 30005850.
80. Loghavi S, Sui D, Wei P, Garcia-Manero G, Pierce S, Routbort MJ, Jabbour EJ, Pemmaraju N, Kanagal-Shamanna R, Gur HD, Hu S, Zuo Z, Medeiros LJ, Kantarjian HM, Khoury JD. Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories. Blood Adv 2(15):1807-1816, 2018. e-Pub 2018. PMID: 30054307.
81. Wang W, Routbort MJ, Loghavi S, Tang Z, Medeiros LJ, Wang SA. Characterization of chronic myelomonocytic leukemia with TP53 mutations. Leuk Res 70:97-99, 2018. e-Pub 2018. PMID: 29908419.
82. Chen H, Luthra R, Routbort MJ, Patel KP, Cabanillas ME, Broaddus RR, Williams MD. Molecular Profile of Advanced Thyroid Carcinomas by Next-Generation Sequencing: Characterizing Tumors Beyond Diagnosis for Targeted Therapy. Mol Cancer Ther 17(7):1575-1584, 2018. e-Pub 2018. PMID: 29695638.
83. Gur HD, Loghavi S, Garcia-Manero G, Routbort M, Kanagal-Shamanna R, Quesada A, Khogeer H, Pierce S, Medeiros LJ, Kantarjian H, Khoury JD. Chronic Myelomonocytic Leukemia With Fibrosis Is a Distinct Disease Subset With Myeloproliferative Features and Frequent JAK2 p.V617F Mutations. Am J Surg Pathol 42(6):799-806, 2018. e-Pub 2018. PMID: 29596070.
84. Kurt H, Bueso-Ramos CE, Khoury JD, Routbort MJ, Kanagal-Shamanna R, Patel UV, Jorgensen JL, Wang SA, Ravandi F, DiNardo C, Luthra R, Medeiros LJ, Patel KP. Characterization of IDH1 p.R132H Mutant Clones Using Mutation-specific Antibody in Myeloid Neoplasms. Am J Surg Pathol 42(5):569-577, 2018. e-Pub 2018. PMID: 29635257.
85. Middleton LP, Phipps R, Routbort M, Prieto V, Medeiros LJ, Riben M, Contreras A, Kelley J, Patel K, Bingham J, Wagar EA. Fifteen-Year Journey to High Reliability in Pathology and Laboratory Medicine. Am J Med Qual 33(5):1062860618759198, 2018. e-Pub 2018. PMID: 29512395.
86. Mehrotra M, Singh RR, Loghavi S, Duose DY, Barkoh BA, Behrens C, Patel KP, Routbort MJ, Kopetz S, Broaddus RR, Jeffrey Medeiros L, Wistuba II, Luthra R. Detection of somatic mutations in cell-free DNA in plasma and correlation with overall survival in patients with solid tumors. Oncotarget 9(12):10259-10271, 2018. e-Pub 2018. PMID: 29535804.
87. Quesada AE, Hu Z, Routbort MJ, Patel KP, Luthra R, Loghavi S, Zuo Z, Yin CC, Kanagal-Shamanna R, Wang SA, Jorgensen JL, Medeiros LJ, Ok CY. Mixed phenotype acute leukemia contains heterogeneous genetic mutations by next-generation sequencing. Oncotarget 9(9):8441-8449, 2018. e-Pub 2018. PMID: 29492206.
88. Fang L, Chen H, Tang Z, Kalhor N, Liu CH, Yao H, Hu S, Lin P, Zhao J, Luthra R, Singh RR, Routbort MJ, Hong D, Medeiros LJ, Lu X. MET amplification assessed using optimized FISH reporting criteria predicts early distant metastasis in patients with non-small cell lung cancer. Oncotarget 9(16):12959-12970, 2018. e-Pub 2018. PMID: 29560123.
89. Kurt H, Zheng L, Kantarjian HM, Tang G, Ravandi-Kashani F, Garcia-Manero G, Gong Z, Amin HM, Konoplev SN, Routbort MJ, Han X, Wang W, Medeiros LJ, Hu S. Secondary Philadelphia chromosome acquired during therapy of acute leukemia and myelodysplastic syndrome. Mod Pathol 31(7):1141-1154, 2018. e-Pub 2018. PMID: 29449681.
90. Oba J, Kim SH, Wang WL, Macedo MP, Carapeto F, McKean MA, Van Arnam J, Eterovic AK, Sen S, Kale CR, Yu X, Haymaker CL, Routbort M, Haydu LE, Bernatchez C, Lazar AJ, Grimm EA, Hong DS, Woodman SE. Targeting the HGF/MET Axis Counters Primary Resistance to KIT Inhibition in KIT-Mutant Melanoma. JCO Precis Oncol 2018:1-8, 2018. e-Pub 2018. PMID: 30094412.
91. Montes-Moreno S, Routbort MJ, Lohman EJ, Barkoh BA, Kanagal-Shamanna R, Bueso-Ramos CE, Singh RR, Medeiros LJ, Luthra R, Patel KP. Clinical molecular testing for ASXL1 c.1934dupG p.Gly646fs mutation in hematologic neoplasms in the NGS era. PLoS One 13(9):e0204218, 2018. e-Pub 2018. PMID: 30222780.
92. Nagarajan R, Bartley AN, Bridge JA, Jennings LJ, Kamel-Reid S, Kim A, Lazar AJ, Lindeman NI, Moncur J, Rai AJ, Routbort MJ, Vasalos P, Merker JD. A Window Into Clinical Next-Generation Sequencing-Based Oncology Testing Practices. Arch Pathol Lab Med 141(12):1679-1685, 2017. e-Pub 2017. PMID: 29028368.
93. Wang W, Routbort MJ, Tang Z, Ok CY, Patel KP, Daver N, Garcia-Manero G, Medeiros LJ, Wang SA. Characterization of TP53 mutations in low-grade myelodysplastic syndromes and myelodysplastic syndromes with a non-complex karyotype. Eur J Haematol 99(6):536-543, 2017. e-Pub 2017. PMID: 28926144.
94. Loree JM, Pereira AA, Lam M, Willauer AN, Raghav K, Dasari A, Morris VK, Advani SM, Menter DG, Eng C, Shaw K, Broaddus R, Routbort MJ, Liu Y, Morris J, Luthra R, Meric-Bernstam F, Overman MJ, Maru DM, Kopetz S. Classifying colorectal cancer by tumor location rather than sidedness highlights a continuum in mutation profiles and Consensus Molecular Subtypes. Clin Cancer Res 24(5):1062-1072, 2017. e-Pub 2017. PMID: 29180604.
95. Brusco LL, Wathoo C, Mills Shaw KR, Holla VR, Bailey AM, Johnson AM, Khotskaya YB, Litzenburger BC, Sanchez NS, Zeng J, Bernstam EV, Eng C, Kee BK, Amaria RN, Routbort MJ, Mills GB, Mendelsohn J, Meric-Bernstam F. Physician interpretation of genomic test results and treatment selection. Cancer 124(5):966-972, 2017. e-Pub 2017. PMID: 29165790.
96. Hughes KS, Ambinder EP, Hess GP, Yu PP, Bernstam EV, Routbort MJ, Clemenceau JR, Hamm JT, Febbo PG, Domchek SM, Chen JL, Warner JL, Members OPO. Identifying Health Information Technology Needs of Oncologists to Facilitate the Adoption of Genomic Medicine: Recommendations From the 2016 American Society of Clinical Oncology Omics and Precision Oncology Workshop. J Clin Oncol 35(27):JCO2017741744, 2017. e-Pub 2017. PMID: 28737972.
97. Kanagal-Shamanna R, Loghavi S, DiNardo CD, Medeiros LJ, Garcia-Manero G, Jabbour E, Routbort MJ, Luthra R, Bueso-Ramos CE, Khoury JD. Bone marrow pathologic abnormalities in familial platelet disorder with propensity for myeloid malignancy and germline RUNX1 mutation. Haematologica 102(10):1661-1670, 2017. e-Pub 2017. PMID: 28659335.
98. Wang W, Routbort MJ, Ok CY, Patel KP, Sun Y, Kanagal-Shamanna R, Medeiros LJ, Wang SA. Characterization of TP53 mutations in clonal cytopenia of undetermined significance. Am J Hematol 92(8):E175-E177, 2017. e-Pub 2017. PMID: 28494520.
99. Mehrotra M, Singh RR, Chen W, Huang RSP, Almohammedsalim AA, Barkoh BA, Simien CM, Hernandez M, Behrens C, Patel KP, Routbort MJ, Broaddus RR, Medeiros LJ, Wistuba II, Kopetz S, Luthra R. Study of Preanalytic and Analytic Variables for Clinical Next-Generation Sequencing of Circulating Cell-Free Nucleic Acid. J Mol Diagn 19(4):514-524, 2017. e-Pub 2017. PMID: 28506684.
100. GENIE Consortium AP. AACR Project GENIE: Powering Precision Medicine through an International Consortium. Cancer Discov, 2017. e-Pub 2017. PMID: 28572459.
101. Kim DW, Haydu LE, Joon AY, Bassett RL, Siroy AE, Tetzlaff MT, Routbort MJ, Amaria RN, Wargo JA, McQuade JL, Kemnade J, Hwu P, Woodman SE, Roszik J, Kim KB, Gershenwald JE, Lazar AJ, Davies MA. Clinicopathological features and clinical outcomes associated with TP53 and BRAF Non-V600 mutations in cutaneous melanoma patients. Cancer 123(8):1372-1381, 2017. e-Pub 2016. PMID: 27911979.
102. Roy-Chowdhuri S, Chen H, Singh RR, Krishnamurthy S, Patel KP, Routbort MJ, Manekia J, Barkoh BA, Yao H, Sabir S, Broaddus RR, Medeiros LJ, Staerkel G, Stewart J, Luthra R. Concurrent fine needle aspirations and core needle biopsies: a comparative study of substrates for next-generation sequencing in solid organ malignancies. Mod Pathol 30(4):499-508, 2017. e-Pub 2017. PMID: 28084342.
103. Mehrotra M, Luthra R, Abraham R, Mishra BM, Virani S, Chen H, Routbort MJ, Patel KP, Medeiros LJ, Singh RR. Validation of quantitative PCR-based assays for detection of gene copy number aberrations in formalin-fixed, paraffin embedded solid tumor samples. Cancer Genet 212-213:24-31, 2017. e-Pub 2017. PMID: 28449808.
104. Sarshekeh AM, Advani S, Overman MJ, Manyam G, Kee BK, Fogelman DR, Dasari A, Raghav K, Vilar E, Manuel S, Shureiqi I, Wolff RA, Patel KP, Luthra R, Shaw K, Eng C, Maru DM, Routbort MJ, Meric-Bernstam F, Kopetz S. Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer. PLoS One 12(3):e0173345, 2017. e-Pub 2017. PMID: 28267766.
105. Luthra R, Patel KP, Routbort MJ, Broaddus RR, Yau J, Simien C, Chen W, Hatfield DZ, Medeiros LJ, Singh RR. A Targeted High-Throughput Next-Generation Sequencing Panel for Clinical Screening of Mutations, Gene Amplifications, and Fusions in Solid Tumors. J Mol Diagn 19(2):255-264, 2017. e-Pub 2017. PMID: 28017569.
106. Lih CJ, Harrington RD, Sims DJ, Harper KN, Bouk CH, Datta V, Yau J, Singh RR, Routbort MJ, Luthra R, Patel KP, Mantha GS, Krishnamurthy S, Ronski K, Walther Z, Finberg KE, Canosa S, Robinson H, Raymond A, Le LP, McShane LM, Polley EC, Conley BA, Doroshow JH, Iafrate AJ, Sklar JL, Hamilton SR, Williams PM. Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal-Finding Clinical Trial: Molecular Analysis for Therapy Choice Clinical Trial. Journal of Molecular Diagnostics 19(2):313-327, 2017. e-Pub 2017. PMID: 28188106.
107. Ballester LY, Fuller GN, Powell SZ, Sulman EP, Patel KP, Luthra R, Routbort MJ. Retrospective Analysis of Molecular and Immunohistochemical Characterization of 381 Primary Brain Tumors. J Neuropathol Exp Neurol 76(3):179-188, 2017. e-Pub 2017. PMID: 28395087.
108. Arango NP, Brusco L, Mills Shaw KR, Chen K, Eterovic AK, Holla V, Johnson A, Litzenburger B, Khotskaya YB, Sanchez N, Bailey A, Zheng X, Horombe C, Kopetz S, Farhangfar CJ, Routbort M, Broaddus R, Bernstam EV, Mendelsohn J, Mills GB, Meric-Bernstam F. A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory. Oncotarget 8(26):41806-41814, 2017. e-Pub 2017. PMID: 28415679.
109. Chen H, Singh RR, Lu X, Huo L, Yao H, Aldape K, Abraham R, Virani S, Mehrotra M, Mishra BM, Bousamra A, Albarracin C, Wu Y, Roy-Chowdhuri S, Shamanna RK, Routbort MJ, Medeiros LJ, Patel KP, Broaddus R, Sahin A, Luthra R. Genome-wide copy number aberrations and HER2 and FGFR1 alterations in primary breast cancer by molecular inversion probe microarray. Oncotarget 8(7):10845-10857, 2017. e-Pub 2017. PMID: 28125801.
110. Mehrotra M, Duose DY, Singh RR, Barkoh BA, Manekia J, Harmon MA, Patel KP, Routbort MJ, Medeiros LJ, Wistuba II, Luthra R. Versatile ion S5XL sequencer for targeted next generation sequencing of solid tumors in a clinical laboratory. PLoS One 12(8):e0181968, 2017. e-Pub 2017. PMID: 28767674.
111. Johnson A, Khotskaya YB, Brusco L, Zeng J, Holla V, Bailey AM, Litzenburger BC, Sanchez N, Shufean MA, Piha-Paul S, Subbiah V, Hong D, Routbort M, Broaddus R, Mills Shaw KR, Mills GB, Mendelsohn J, Meric-Bernstam F. Clinical Use of Precision Oncology Decision Support. JCO Precis Oncol 2017(1):1-12, 2017. e-Pub 2017. PMID: 30320296.
112. Huang L, Garcia-Manero G, Jabbour E, Goswami M, Routbort MJ, Medeiros LJ, Jorgensen JL, Wang SA. Persistence of immunophenotypically aberrant CD34+ myeloid progenitors is frequent in bone marrow of patients with myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms treated with hypomethylating agents. J Clin Pathol 69(11):1001-1008, 2016. e-Pub 2016. PMID: 27083210.
113. Singh RR, Mehrotra M, Chen H, Almohammedsalim AA, Sahin A, Bosamra A, Patel KP, Routbort MJ, Lu X, Ronald A, Mishra BM, Virani S, Medeiros LJ, Luthra R. Comprehensive Screening of Gene Copy Number Aberrations in Formalin-Fixed, Paraffin-Embedded Solid Tumors Using Molecular Inversion Probe-Based Single-Nucleotide Polymorphism Array. Journal of Molecular Diagnostics 18(5):676-87, 2016. e-Pub 2016. PMID: 27392636.
114. Roy S, LaFramboise WA, Nikiforov YE, Nikiforova MN, Routbort MJ, Pfeifer J, Nagarajan R, Carter AB, Pantanowitz L. Next-Generation Sequencing Informatics: Challenges and Strategies for Implementation in a Clinical Environment. Arch Pathol Lab Med 140(9):958-75, 2016. e-Pub 2016. PMID: 26901284.
115. DiNardo CD, Bannon SA, Routbort M, Franklin A, Mork M, Armanios M, Mace EM, Orange JS, Jeff-Eke M, Churpek JE, Takahashi K, Jorgensen JL, Garcia-Manero G, Kornblau S, Bertuch A, Cheung H, Bhalla K, Futreal A, Godley LA, Patel KP. Evaluation of patients and families with concern for predispositions to hematologic malignancies within the hereditary hematologic malignancy clinic (HHMC). Clin Lymphoma Myeloma Leuk 16(7):417-428.e2, 2016. e-Pub 2016. PMID: 27210295.
116. Yabe M, Medeiros LJ, Tang G, Wang SA, Ahmed S, Nieto Y, Hu S, Bhagat G, Oki Y, Patel KP, Routbort M, Luthra R, Fanale MA, Bueso-Ramos CE, Jorgensen JL, Vega F, Chen W, Hoehn D, Konoplev S, Milton DR, Wistuba I, Li S, You MJ, Young KH, Miranda RN. Prognostic Factors of Hepatosplenic T-cell Lymphoma: Clinicopathologic Study of 28 Cases. Am J Surg Pathol 40(5):676-88, 2016. e-Pub 2016. PMID: 26872013.
117. Meric-Bernstam F, Brusco L, Daniels M, Wathoo C, Bailey AM, Strong L, Shaw K, Lu K, Qi Y, Zhao H, Lara-Guerra H, Litton J, Arun B, Eterovic AK, Aytac U, Routbort M, Subbiah V, Janku F, Davies MA, Kopetz S, Mendelsohn J, Mills GB, Chen K. Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol. Ann Oncol 27(5):795-800, 2016. e-Pub 2016. PMID: 26787237.
118. Kanagal-Shamanna R, Singh RR, Routbort MJ, Patel KP, Medeiros LJ, Luthra R. Principles of analytical validation of next-generation sequencing based mutational analysis for hematologic neoplasms in a CLIA-certified laboratory. Expert Rev Mol Diagn 16(4):1-12, 2016. e-Pub 2016. PMID: 26765348.
119. DiNardo CD, Jabbour E, Ravandi F, Takahashi K, Daver N, Routbort M, Patel KP, Brandt M, Pierce S, Kantarjian H, Garcia-Manero G. IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression. Leukemia 30(4):980-984, 2016. e-Pub 2016. PMID: 26228814.
120. Aye le L, Loghavi S, Young KH, Siddiqi I, Yin CC, Routbort MJ, Liang M, Eilerman K, Medeiros LJ, Brynes RK, Bueso-Ramos C. Preleukemic phase of chronic myelogenous leukemia: morphologic and immunohistochemical characterization of 7 cases. Ann Diagn Pathol 21:53-8, 2016. e-Pub 2016. PMID: 27040932.
121. Yabe M, Medeiros LJ, Tang G, Wang SA, P Patel K, Routbort M, Bhagat G, Bueso-Ramos CE, Jorgensen JL, Luthra R, Chen W, Muzzafar T, Kanagal-Shamanna R, Khoury JD, Daneshbod Y, Davanlou M, Li S, Young KH, Miranda RN. Dyspoietic changes associated with hepatosplenic T-cell lymphoma are not a manifestation of a myelodysplastic syndrome: analysis of 25 patients. Hum Pathol 50:109-17, 2016. e-Pub 2016. PMID: 26997444.
122. Kanagal-Shamanna R, Luthra R, Yin CC, Patel KP, Takahashi K, Lu X, Lee J, Zhao C, Stingo F, Zuo Z, Routbort MJ, Singh RR, Fox P, Ravandi F, Garcia-Manero G, Medeiros LJ, Bueso-Ramos CE. Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS. Oncotarget 7(12):14251-14258, 2016. e-Pub 2016. PMID: 26883102.
123. Loghavi S, Bueso-Ramos CE, Kanagal-Shamanna R, Young Ok C, Salim AA, Routbort MJ, Mehrotra M, Verstovsek S, Medeiros LJ, Luthra R, Patel KP. Myeloproliferative neoplasms with calreticulin mutations exhibit distinctive morphologic features. Am J Clin Pathol 145(3):418-27, 2016. e-Pub 2016. PMID: 27124925.
124. Goswami RS, Luthra R, Singh RR, Patel KP, Routbort MJ, Aldape KD, Yao H, Dang HD, Barkoh BA, Manekia J, Medeiros LJ, Roy-Chowdhuri S, Stewart J, Broaddus RR, Chen H. Identification of factors affecting the success of Next-Generation sequencing testing in solid tumors. Am J Clin Pathol 145(2):222-37, 2016. e-Pub 2016. PMID: 27124905.
125. Ok CY, Patel KP, Garcia-Manero G, Routbort MJ, Peng J, Tang G, Goswami M, Young KH, Singh R, Medeiros LJ, Kantarjian HM, Luthra R, Wang SA. TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases. J Hematol Oncol 8(1):45, 2015. e-Pub 2015. PMID: 25952993.
126. Roy-Chowdhuri S, de Melo Gagliato D, Routbort MJ, Patel KP, Singh RR, Broaddus R, Lazar AJ, Sahin A, Alvarez RH, Moulder S, Wheler JJ, Janku F, Gonzalez-Angulo AM, Chavez-MacGregor M, Valero V, Ueno NT, Mills G, Mendelsohn J, Yao H, Aldape K, Luthra R, Meric-Bernstam F. Multigene Clinical Mutational Profiling of Breast Carcinoma Using Next-Generation Sequencing. Am J Clin Pathol 144(5):713-21, 2015. e-Pub 2015. PMID: 26486734.
127. Ok CY, Xu-Monette ZY, Li L, Manyam GC, Montes-Moreno S, Tzankov A, Visco C, Dybkær K, Routbort MJ, Zhang L, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Parsons BM, Rao H, Møller MB, Winter JN, Piris MA, Wang SA, Medeiros LJ, Young KH. Evaluation of NF-κB subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions. Mod Pathol 28(9):1202-1213, 2015. e-Pub 2015. PMID: 26111978.
128. Raju GS, Lum PJ, Slack RS, Thirumurthi S, Lynch PM, Miller E, Weston BR, Davila ML, Bhutani MS, Shafi MA, Bresalier RS, Dekovich AA, Lee JH, Guha S, Pande M, Blechacz B, Rashid A, Routbort M, Shuttlesworth G, Mishra L, Stroehlein JR, Ross WA. Natural language processing as an alternative to manual reporting of colonoscopy quality metrics. Gastrointest Endosc 82(3):512-519, 2015. e-Pub 2015. PMID: 25910665.
129. Meric-Bernstam F, Brusco L, Shaw K, Horombe C, Kopetz S, Davies MA, Routbort M, Piha-Paul SA, Janku F, Ueno N, Hong D, De Groot J, Ravi V, Li Y, Luthra R, Patel K, Broaddus R, Mendelsohn J, Mills GB. Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. J Clin Oncol 33(25):2753-2762, 2015. e-Pub 2015. PMID: 26014291.
130. Patel KP, Newberry KJ, Luthra R, Jabbour E, Pierce S, Cortes J, Singh R, Mehrotra M, Routbort MJ, Luthra M, Manshouri T, Santos FP, Kantarjian H, Verstovsek S. Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib. Blood 126(6):790-797, 2015. e-Pub 2015. PMID: 26124496.
131. Shen Q, Ouyang J, Tang G, Jabbour EJ, Garcia-Manero G, Routbort M, Konoplev S, Bueso-Ramos C, Jeffrey Medeiros L, Jorgensen JL, Wang SA. Flow Cytometry Immunophenotypic Findings in Chronic Myelomonocytic Leukemia and Its Utility in Monitoring Treatment Response. Eur J Haematol 95(2):168-176, 2015. e-Pub 2014. PMID: 25354960.
132. DiNardo CD, Ravandi F, Agresta S, Konopleva M, Takahashi K, Kadia T, Routbort M, Patel KP, Brandt M, Pierce S, Garcia-Manero G, Cortes J, Kantarjian H. Characteristics, clinical outcome and prognostic significance of IDH mutations in AML. Am J Hematol 90(8):732-736, 2015. e-Pub 2015. PMID: 26016821.
133. Tetzlaff MT, Pattanaprichakul P, Wargo J, Fox PS, Patel KP, Estrella JS, Broaddus RR, Williams MD, Davies MA, Routbort MJ, Lazar AJ, Woodman SE, Hwu WJ, Gershenwald JE, Prieto VG, Torres-Cabala CA, Curry JL. Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma. Hum Pathol 46(8):1101-10, 2015. e-Pub 2015. PMID: 26058727.
134. Roy-Chowdhuri S, Goswami RS, Chen H, Patel KP, Routbort MJ, Singh RR, Broaddus RR, Barkoh BA, Manekia J, Yao H, Medeiros LJ, Staerkel G, Luthra R, Stewart J. Factors affecting the success of next-generation sequencing in cytology specimens. Cancer Cytopathol, 2015. e-Pub 2015. PMID: 26230354.
135. Meric-Bernstam F, Johnson A, Holla V, Bailey AM, Brusco L, Chen K, Routbort M, Patel KP, Zeng J, Kopetz S, Davies MA, Piha-Paul SA, Hong DS, Eterovic AK, Tsimberidou AM, Broaddus R, Bernstam EV, Shaw KR, Mendelsohn J, Mills GB. A Decision Support Framework for Genomically Informed Investigational Cancer Therapy. J Natl Cancer Inst 107(7), 2015. e-Pub 2015. PMID: 25863335.
136. Ouyang J, Goswami M, Tang G, Peng J, Ravandi F, Daver N, Routbort M, Konoplev S, Lin P, Medeiros LJ, Jorgensen JL, Wang SA. The clinical significance of negative flow cytometry immunophenotypic results in a morphologically scored positive bone marrow in patients following treatment for acute myeloid leukemia. Am J Hematol 90(6):504-510, 2015. e-Pub 2015. PMID: 25732229.
137. Goswami RS, Patel KP, Singh RR, Meric-Bernstam F, Kopetz S, Subbiah V, Alvarez RH, Davies MA, Jabbar KJ, Roy Chowdhuri S, Lazar AJ, Medeiros LJ, Broaddus RR, Luthra R, Routbort MJ. Hotspot mutation panel testing reveals clonal evolution in a study of 265 paired primary and metastatic tumors. Clin Cancer Res 21(11):2644-2651, 2015. e-Pub 2015. PMID: 25695693.
138. Stockman DL, Curry JL, Torres-Cabala CA, Watson IR, Siroy AE, Bassett RL, Zou L, Patel KP, Luthra R, Davies MA, Wargo JA, Routbort MA, Broaddus RR, Prieto VG, Lazar AJ, Tetzlaff MT. Use of clinical next-generation sequencing to identify melanomas harboring SMARCB1 mutations. J Cutan Pathol 42(5):308-317, 2015. e-Pub 2015. PMID: 25754356.
139. Campos-Gomez S, Lara-Guerra H, Routbort MJ, Lu X, Simon GR. Lung adenocarcinoma with concurrent KRAS mutation and ALK rearrangement responding to crizotinib: case report. Int J Biol Markers 30(2):0, 2015. e-Pub 2014. PMID: 25588859.
140. Jabbar KJ, Luthra R, Patel KP, Singh RR, Goswami R, Aldape KD, Medeiros LJ, Routbort MJ. Comparison of Next-generation Sequencing Mutation Profiling With BRAF and IDH1 Mutation-specific Immunohistochemistry. Am J Surg Pathol 39(4):454-461, 2015. e-Pub 2015. PMID: 25634750.
141. Ok CY, Patel KP, Garcia-Manero G, Routbort MJ, Fu B, Tang G, Goswami M, Singh R, Kanagal-Shamanna R, Pierce SA, Young KH, Kantarjian HM, Medeiros LJ, Luthra R, Wang SA. Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases. Leuk Res 39(3):348-354, 2015. e-Pub 2014. PMID: 25573287.
142. Chen K, Meric-Bernstam F, Zhao H, Zhang Q, Ezzeddine N, Tang LY, Qi Y, Mao Y, Chen T, Chong Z, Zhou W, Zheng X, Johnson A, Aldape KD, Routbort MJ, Luthra R, Kopetz S, Davies MA, de Groot J, Moulder S, Vinod R, Farhangfar CJ, Mills Shaw K, Mendelsohn J, Mills GB, Karina Eterovic A. Clinical Actionability Enhanced through Deep Targeted Sequencing of Solid Tumors. Clin Chem 61(3):544-553, 2015. e-Pub 2015. PMID: 25626406.
143. Siroy AE, Boland GM, Milton DR, Roszik J, Frankian S, Malke J, Haydu L, Prieto VG, Tetzlaff M, Ivan D, Wang WL, Torres-Cabala C, Curry J, Roy-Chowdhuri S, Broaddus R, Rashid A, Stewart J, Gershenwald JE, Amaria RN, Patel SP, Papadopoulos NE, Bedikian A, Hwu WJ, Hwu P, Diab A, Woodman SE, Aldape KD, Luthra R, Patel KP, Shaw KR, Mills GB, Mendelsohn J, Meric-Bernstam F, Kim KB, Routbort MJ, Lazar AJ, Davies MA. Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma. J Invest Dermatol 135(2):508-15, 2015. e-Pub 2015. PMID: 25148578.
144. Boland GM, Piha-Paul SA, Subbiah V, Routbort M, Herbrich SM, Baggerly K, Patel KP, Brusco L, Horombe C, Naing A, Fu S, Hong DS, Janku F, Johnson A, Broaddus R, Luthra R, Shaw K, Mendelsohn J, Mills GB, Meric-Bernstam F. Clinical next generation sequencing to identify actionable aberrations in a phase I program. Oncotarget 6(24):20099-20110, 2015. e-Pub 2015. PMID: 26015395.
145. Zhou W, Zhao H, Chong Z, Routbort MJ, Eterovic AK, Meric-Bernstam F, Chen K. ClinSeK: a targeted variant characterization framework for clinical sequencing. Genome Med 7(1):34, 2015. e-Pub 2015. PMID: 25918555.
146. Singh RR, Patel KP, Routbort MJ, Aldape K, Lu X, Manekia J, Abraham R, Reddy NG, Barkoh BA, Veliyathu J, Medeiros LJ, Luthra R. Clinical massively parallel next-generation sequencing analysis of 409 cancer-related genes for mutations and copy number variations in solid tumours. Br J Cancer 111(10):2014-2023, 2014. e-Pub 2014. PMID: 25314059.
147. Loghavi S, Zuo Z, Ravandi F, Kantarjian HM, Bueso-Ramos C, Zhang L, Singh RR, Patel KP, Medeiros L, Stingo F, Routbort M, Cortes J, Luthra R, Khoury JD. Clinical features of De Novo acute myeloid leukemia with concurrent DNMT3A , FLT3 and NPM1 mutations. J Hematol Oncol 7(1):74, 2014. e-Pub 2014. PMID: 25281355.
148. Zhang L, Singh RR, Patel KP, Stingo F, Routbort M, You MJ, Miranda RN, Garcia-Manero G, Kantarjian HM, Medeiros LJ, Luthra R, Khoury JD. BRAF Kinase domain mutations are present in a subset of chronic myelomonocytic leukemia with Wild-Type RAS. Am J Hematol 89(5):499-504, 2014. e-Pub 2014. PMID: 24446311.
149. Portier BP, Kanagal-Shamanna R, Luthra R, Singh R, Routbort MJ, Handal B, Reddy N, Barkoh BA, Zuo Z, Medeiros LJ, Aldape K, Patel KP. Quantitative assessment of mutant allele burden in solid tumors by semiconductor-based next-generation sequencing. Am J Clin Pathol 141(4):559-72, 2014. e-Pub 2014. PMID: 24619758.
150. Luthra R, Patel KP, Reddy NG, Haghshenas V, Routbort MJ, Harmon MA, Barkoh BA, Kanagal-Shamanna R, Ravandi F, Cortes JE, Kantarjian HM, Medeiros LJ, Singh RR. Next Generation Sequencing based Multi-Gene Mutational Screen for Acute Myeloid Leukemia using MiSeq: Applicability for Diagnostics and Disease Monitoring. Haematologica 99(3):465-73, 2014. e-Pub 2014. PMID: 24142997.
151. Guimarães MD, Marchiori E, Marom EM, Routbort MJ, Godoy MC. Pulmonary granulocytic sarcoma (chloroma) mimicking an opportunistic infection in a patient with acute myeloid leukemia. Ann Hematol 93(2):327-328, 2014. e-Pub 2014. PMID: 23624529.
152. Kanagal-Shamanna R, Portier BP, Singh RR, Routbort MJ, Aldape KD, Handal BA, Rahimi H, Reddy NG, Barkoh BA, Mishra BM, Paladugu AV, Manekia JH, Kalhor N, Chowdhuri SR, Staerkel GA, Medeiros LJ, Luthra R, Patel KP. Next-generation sequencing-based multi-gene mutation profiling of solid tumors using fine needle aspiration samples: promises and challenges for routine clinical diagnostics. Mod Pathol 27(2):314-327, 2014. e-Pub 2013. PMID: 23907151.
153. Bailey AM, Mao Y, Zeng J, Holla V, Johnson A, Brusco L, Chen K, Mendelsohn J, Routbort MJ, Mills GB, Meric-Bernstam F. Implementation of biomarker-driven cancer therapy: existing tools and remaining gaps. Discov Med 17(92):101-14, 2014. e-Pub 2014. PMID: 24534473.
154. Zhou Y, Fan X, Routbort M, Cameron Yin C, Singh R, Bueso-Ramos C, Thomas DA, Milton DR, Medeiros LJ, Lin P. Absence of terminal deoxynucleotidyl transferase expression identifies a subset of high-risk adult T-lymphoblastic leukemia/lymphoma. Mod Pathol 26(10):1338-1345, 2013. e-Pub 2013. PMID: 23702731.
155. Singh RR, Patel KP, Routbort MJ, Reddy NG, Barkoh BA, Handal B, Kanagal-Shamanna R, Greaves WO, Medeiros LJ, Aldape KD, Luthra R. Clinical Validation of a Next Generation Sequencing Screen for Mutational Hotspots in 46 Cancer-related Genes. J Mol Diagn 15(5):607-22, 2013. e-Pub 2013. PMID: 23810757.
156. Alayed K, Patel KP, Konoplev SN, Singh R, Routbort MJ, Reddy N, Pemmaraju N, Zhang L, Al Shaikh A, Aladily T, Jain N, Luthra R, Medeiros LJ, Khoury JD. TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow. Am J Hematol 88(12):1055-1061, 2013. e-Pub 2013. PMID: 23940084.
157. Hwang JP, Fisch MJ, Zhang H, Kallen MA, Routbort MJ, Lal LS, Vierling JM, Suarez-Almazor ME. Low Rates of Hepatitis B Virus Screening at the Onset of Chemotherapy. J Oncol Pract 8(4):e32-9, 2012. e-Pub 2012. PMID: 23180996.
158. Lin P, Dickason TJ, Fayad LE, Lennon PA, Hu P, Garcia M, Routbort MJ, Miranda R, Wang X, Qiao W, Medeiros LJ. Prognostic value of MYC rearrangement in cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. Cancer 118(6):1566-73, 2012. e-Pub 2012. PMID: 21882178.
159. Leung AA, Lou JJ, Mareninov S, Silver SS, Routbort MJ, Riben M, Andrechak G, Yong WH. Tolerance testing of passive radio frequency identification tags for solvent, temperature, and pressure conditions encountered in an anatomic pathology or biorepository setting. J Pathol Inform 1(21):1-6, 2010. e-Pub 2010. PMID: 21031010.
160. Talwalkar SS, Miranda RN, Valbuena JR, Routbort MJ, Martin AW, Medeiros LJ. Lymphomas involving the breast: a study of 106 cases comparing localized and disseminated neoplasms. Am J Surg Pathol 32(9):1299-309, 2008. e-Pub 2008. PMID: 18636016.
161. Riben M, Routbort M, Nesbitt L, Ninan S. Real-time process defect collection within the anatomic pathology aboratory to facilitate informatics driven workflow optimization. AMIA Annu Symp Proc:1110, 2008. e-Pub 2008. PMID: 18999113.
162. Thompson MA, Habra MA, Routbort MJ, Holsinger FC, Perrier ND, Waguespack SG, Rodriguez MA. Primary adrenal natural killer/T-cell nasal type lymphoma: First case report in adults. Am J Hematol 82(4):299-303, 2006. e-Pub 2006. PMID: 17094095.
163. Chen W, Rassidakis GZ, Li J, Routbort M, Jones D, Kantarjian H, Medeiros LJ, Bueso-Ramos CE. High frequency of NPM1 gene mutations in acute myeloid leukemia with prominent nuclear invaginations ("cuplike" nuclei). Blood 108(5):1783-4, 2006. e-Pub 2006. PMID: 16926303.
164. Volmar KE, Vollmer RT, Routbort MJ, Creager AJ. Pancreatic and bile duct brushing cytology in 1000 cases: review of findings and comparison of preparation methods. Cancer 108(4):231-8, 2006. e-Pub 2006. PMID: 16541448.
165. Gong JZ, Bayerl MG, Sandhaus LM, Sebastian S, Rehder CW, Routbort M, Lagoo AS, Szabolcs P, Chiu J, Comito M, Buckley PJ. Posttransplant lymphoproliferative disorder after umbilical cord blood transplantation in children. Am J Surg Pathol 30(3):328-36, 2006. e-Pub 2006. PMID: 16538052.
166. Volmar KE, Routbort MJ, Jones CK, Xie HB. Primary pancreatic lymphoma evaluated by fine-needle aspiration: findings in 14 cases. Am J Clin Pathol 121(6):898-903, 2004. e-Pub 2004. PMID: 15198364.
167. Binder DK, Routbort MJ, McNamara JO. Immunohistochemical evidence of seizure-induced activation of trk receptors in the mossy fiber pathway of adult rat hippocampus. J Neurosci 19(11):4616-26, 1999. e-Pub 1999. PMID: 10341259.
168. Binder DK, Routbort MJ, Ryan TE, Yancopoulos GD, McNamara JO. Selective inhibition of kindling development by intraventricular administration of TrkB receptor body. J Neurosci 19(4):1424-36, 1999. e-Pub 1999. PMID: 9952419.
169. Routbort MJ, Bausch SB, McNamara JO. Seizures, cell death, and mossy fiber sprouting in kainic acid-treated organotypic hippocampal cultures. Neuroscience 94(3):755-65, 1999. e-Pub 1999. PMID: 10579566.
170. Fu JL, Stein S, Rosenstein L, Bodwell T, Routbort M, Semler BL, Roos RP. Neurovirulence determinants of genetically engineered Theiler viruses. Proc Natl Acad Sci U S A 87(11):4125-9, 1990. e-Pub 1990. PMID: 2161533.
171. Salazar-Grueso EF, Routbort MJ, Martin J, Dawson G, Roos RP. Polyclonal IgM anti-GM1 ganglioside antibody in patients with motor neuron disease and variants. Ann Neurol 27(5):558-63, 1990. e-Pub 1990. PMID: 2113790.
172. Roos RP, Stein S, Routbort M, Senkowski A, Bodwell T, Wollmann R. Theiler's murine encephalomyelitis virus neutralization escape mutants have a change in disease phenotype. J Virol 63(10):4469-73, 1989. e-Pub 1989. PMID: 2476574.

Review Articles

1. Duncavage EJ, Coleman JF, de Baca ME, Kadri S, Leon A, Routbort M, Roy S, Suarez CJ, Vanderbilt C, Zook JM. Recommendations for the Use of in Silico Approaches for Next-Generation Sequencing Bioinformatic Pipeline Validation: A Joint Report of the Association for Molecular Pathology, Association for Pathology Informatics, and College of American Pathologists. J Mol Diagn 25(1):3-16, 2023. e-Pub 2023. PMID: 36244574.
2. DiNardo CD, Routbort MJ, Bannon SA, Benton CB, Takahashi K, Kornblau SM, Luthra R, Kanagal-Shamanna R, Medeiros LJ, Garcia-Manero G, M Kantarjian H, Futreal PA, Meric-Bernstam F, Patel KP. Improving the detection of patients with inherited predispositions to hematologic malignancies using next-generation sequencing-based leukemia prognostication panels. Cancer 124(13):2704-2713, 2018. e-Pub 2018. PMID: 29682723.
3. Roy-Chowdhuri S, Roy S, Monaco SE, Routbort MJ, Pantanowitz L. Big data from small samples: Informatics of next-generation sequencing in cytopathology. Cancer 125(4):236-244, 2017. e-Pub 2016. PMID: 27918649.
4. Loghavi S, Routbort MJ, Patel KP, Luthra R, Wang WL, Broaddus RR, Davies MA, Lazar AJ. How Do We Make Clinical Molecular Testing for Cancer Standard of Care for Pathology Departments?. J Natl Compr Canc Netw 14(6):787-92, 2016. e-Pub 2016. PMID: 27283170.
5. Singh, RR, Luthra, R, Routbort, MJ, Patel, KP, Medeiros, LJ. Implementation of next generation sequencing in clinical molecular diagnostic laboratories. Expert Review of Precision Medicine and Drug Development 1(1):109-120, 2016. e-Pub 2016.
6. Bueso-Ramos CE, Kanagal-Shamanna R, Routbort MJ, Hanson CA. Therapy-Related Myeloid Neoplasms. Am J Clin Pathol 144(2):207-18, 2015. e-Pub 2015. PMID: 26185306.
7. Chari NS, Pinaire NL, Thorpe L, Medeiros LJ, Routbort MJ, McDonnell TJ. The p53 tumor suppressor network in cancer and the therapeutic modulation of cell death. Apoptosis 14(4):336-47, 2009. e-Pub 2009. PMID: 19229632.

Abstracts

1. Roy-Chowdhuri S, Routbort MJ, Singh R, Broaddus R, Lazar AJ, Rashid A, Chen H, Yemelyanova A, Manekia J, Chen W, Medeiros LJ, Hamilton SR, Luthra R, Patel KP. NP Signature-Based Sample Identification as a Patient Safety Tool in NGS-Based Targeted Oncologic Testing. Journal of Molecular Diagnostics 18(6):1049, 2016. e-Pub 2016.
2. Patel KP, Barkoh BA, Lewing C, Mantha GS, Broaddus R, Routbort MJ, Middleton LP, Phipps RA, Hamilton SR, Medeiros L, Luthra R. Transforming a clinical molecular diagnostics laboratory into a high reliability organization. Journal of Molecular Diagnostics 18(6):1045, 2016. e-Pub 2016.
3. Singh RR, Hatfield DZ, Reddy NG, Shamanna RK, Routbort M, Galbincea JM, Stewart J, Wierda WG, Medeiros L, Luthra R, Patel KP. Development of a targeted Next-Generation Sequencing (NGS) panel for prognostication and detection of treatment resistance in patients with Chronic Lymphocytic Leukemia (CLL). Journal of Molecular Diagnostics 18(6):951, 2016. e-Pub 2016.
4. Loghavi S, Routbort MJ, Kanagal-Shamanna R, Wang SA, Khoury JD, Ok C, Yin CC, Singh RR, Zuo Z, Bueso-Ramos CE, Medeiros L, Luthra R, Patel KP. Myeloid neoplasms with recurrent GNAS mutations. Journal of Molecular Diagnostics 18(6):960, 2016. e-Pub 2016.
5. Quesada AE, Hu Z, Routbort MJ, Patel KP, Luthra R, Loghavi S, Zuo Z, Yin C, Kanagal-Shamana R, Wang SA, Jorgensen JL, Medeiros L, Ok CY. Mixed phenotype acute leukemia contains heterogeneous genetic mutations by Next-Generation sequencing. Journal of Molecular Diagnostics 18(6):961, 2016. e-Pub 2016.
6. Lee S, Broaddus RR, Pattanaprichaku P, Singh RR, Routbort M, Patel KP, Luthra R, Rashid A, Chen H. Molecular characterization of appendiceal mucinous neoplasms: Stratification of KRAS, GNAS, and TP53 mutations by tumor grade. Journal of Molecular Diagnostics 18(6), 2016. e-Pub 2016.
7. Luthra R, Singh RR, Lazar AJ, Wang W, Meis JM, Patel KP, Routbort MJ, Panditi DD, Yau J, Hatfield DZ, Medeiros J. A nanofluidics-based high throughput Real-Time PCR analysis for gene fusions in sarcomas. Journal of Molecular Diagnostics 18(6):1003-1004, 2016. e-Pub 2016.
8. Olar A, Broaddus R, Routbort M, Roy-Chowdhuri S, Hodges KB, Singh RR, Lazar AJ, Rashid A, Chen H, Yemelyanova A, Medeiros JL, Hamilton SR, Luthra R, Patel KP. Value of paired tumor-normal analysis in solid tumor genotyping by Next-Generation sequencing. Journal of Molecular Diagnostics 18(6):1005, 2016. e-Pub 2016.
9. Chen H, Routbort MJ, Rashid A, Roy-Chowdhuri S, Patel KP, Lazar A, Broaddus R, Manekia J, Singh R, Luthra R, Yemelyanova A. Challenges in Next-Generation sequencing analysis of somatic mutations in transplant patients. Journal of Molecular Diagnostics 18(6):1022, 2016. e-Pub 2016.
10. Mehrotra M, Singh RR, Loghavi S, Barkoh BA, Simien C, Hernandez M, Manekia J, Behrens C, Routbort MJ, Patel KP, Kopetz S, Medeiros LJ, Wistuba II, Luthra R. Ultradeep sequencing using semiconductor-based high-throughput Next- Generation sequencing platforms for cell-free DNA genotyping in patients with solid tumors. Journal of Molecular Diagnostics 18(6):1022, 2016. e-Pub 2016.
11. Mehrotra M, Luthra R, Wistuba II, Chen W, Barkoh BA, Montes-Moreno S, Burns C, Dailey D, Bolivar A, Routbort MJ, Medeiros L, Patel KP, Singh RR, Kanagal-Shamanna R. "Single-Gene" next-generation sequencing-based assay for detection of low-level TP53 mutations. Journal of Molecular Diagnostics 18(6):1047-1048, 2016. e-Pub 2016.
12. Yabe M, Medeiros LJ, Tang GL, Wang SA, Patel KP, Routbort MJ, Bhagat G, Bueso-Ramos CE, Jorgensen JL, Luthra R, Chen WV, Muzzafar T, Kanagal-Shamanna R, Khoury JD, Daneshbod T, Davanlou M, Li SY, Young KH, Miranda RN. Dyspoietic changes associated with hepatosplenic T-cell lymphoma are not a manifestation of a myelodysplastic syndrome: analysis of 25 patients. Human Pathology 50:109-117, 2016. e-Pub 2016.
13. Hodjat P, Priyanka P, Ghosh K, Thakral B, Patel KP, Routbort M, Kanagal-Shamana R, Yin CC, Zuo Z, Luthra R, Muzzafar T. Mutation Analysis in 50 Cases of Newly Diagnosed Acute Myeloid Leukemia Arising from Myelodysplastic Syndrome by Next Generation Sequencing: A Clinico-Pathologic Correlation. Modern Pathology 29:350A-351A, 2016. e-Pub 2016.
14. Hodjat P, Priyanka P, Ghosh K, Thakral B, Patel KP, Routbort M, Kanagal-Shamana R, Yin CC, Zuo Z, Luthra R, Muzzafar T. Mutation Analysis in 8 Cases of Newly Diagnosed Acute Myeloid Leukemia Arising from Myeloproliferative Neoplasms by Next Generation Sequencing: A Clinico-Pathologic Correlation. Modern Pathology 29:351A, 2016. e-Pub 2016.
15. Salim AA, Luthra R, Singh R, Patel KP, Routbort M, Barkoh BA, Manekia J, Chowdhuri SR, Broaddus R, Chen H. Pre-Analytical Factors Involved in the Clinical Analysis of a Comprehensive Next-Generation Sequencing Panel. Modern Pathology 29:504A, 2016. e-Pub 2016.
16. Hodjat P, Priyanka P, Ghosh K, Thakral B, Patel KP, Routbort M, Kanagal-Shamana R, Yin CC, Zuo Z, Luthra R, Muzzafar T. Mutation Analysis in 45 Cases of Newly Diagnosed Acute Myeloid Leukemia with Recurrent Cytogenetic Abnormalities by Next Generation Sequencing: A Clinico-Pathologic Correlation. Modern Pathology 29:352A, 2016. e-Pub 2016.
17. Hodjat P, Priyanka P, Ghosh K, Thakral B, Patel KP, Routbort M, Kanagal-Shamana R, Yin CC, Zuo Z, Luthra R, Muzzafar T. Mutation Analysis in 122 Cases of Newly Diagnosed Normal Karyotype Acute Myeloid Leukemia by Next Generation Sequencing: A Clinico-Pathologic Correlation. Modern Pathology 29:351A, 2016. e-Pub 2016.
18. Ghosh K, Hodjat P, Priyanka P, Thakral B, Patel KP, Routbort M, Kanagal-Shamana R, Yin CC, Zuo Z, Luthra R, Muzzafar T. Mutation Analysis in 117 Cases Newly Diagnosed Myelodysplastic Syndrome: IPSS-R High and Very High Risk by Next Generation Sequencing: A Clinico-Pathologic Correlation. Modern Pathology 29:346A-347A, 2016. e-Pub 2016.
19. Quesada A, Luthra R, Patel KP, Singh R, Routbort M, Loghavi S, Khoury JD, Medeiros J, Bueso-Ramos CE, Kanagal-Shamanna R. De Novo Acute Myeloid Leukemia (AML) with RUNX1 Mutations Shows Characteristic Clinicopathologic Features. Modern Pathology 29:371A, 2016. e-Pub 2016.
20. Singh RR, Paladugu AV, Jeter KE, Manekia JH, Routbort MJ, Barkoh BA, Patel KP, Luthra R. Comparison of Ion PGM and Proton Platforms for Targeted Hotspot Mutation Analysis. J Mol Diag 17(6):822-823, 2015. e-Pub 2015.
21. Ok C, Loghavi S, Salim AA, Chen H, Kanagal-Sha, amma R, Chowdhuri SR, Broaddus RR, Lazar AJ, Rashid A, Manekia JH, Barkoh BA, Medeiros L, Singh RR, Routbort MJ, Luthra R, Patel KP. To Confirm or Not to Confirm, That is the Question for Equivocal NGS Findings. JOURNAL OF MOLECULAR DIAGNOSTICS 17(6):810-810, 2015. e-Pub 2015.
22. Ok C, Yang H, Villareal JC, Barkoh BA, Routbort MJ, Singh RR, Mantha GS, Lu H, Medeiros L, Luthra R, Patel KP. Development of a Decision Support System for Specimen Accessioning and Uniform Triaging of Oncologic Molecular Testing. JOURNAL OF MOLECULAR DIAGNOSTICS 17(6):803-804, 2015. e-Pub 2015.
23. Routbort M, Villareal J, Mantha G, Reddy N, Harmon A, Liu W, Riggins D, Patel KP, Luthra R. High Throughput, High Fidelity Sample Management Using Robotic Tube Labeling and Scanning with a Generalizable Software Toolkit. J Mol Diag 17(6):811-811, 2015. e-Pub 2015.
24. Chen H, Lu X, Singh R, Huo L, Bousamra A, Abraham R, Virani S, Mehrotra M, Mishra B, Roy-Chowdhuri S, Routbort M, Kenneth A, Broaddus R, Yao H, Sahin A, Patel KP, Luthra R. Quantitative Assessment of ESR, PGR and Genome-Wide Copy Number Aberrations in Advanced Breast Cancer by SNP Microarray. JOURNAL OF MOLECULAR DIAGNOSTICS 17(6):840-840, 2015. e-Pub 2015.
25. Chen WV, Reddy N, Jiao O, Suh E, Galbincea J, Singh RR, Patel KP, Luthra R, Routbort M. A Custom HiSeq Bioinformatics Pipeline for TruSeq Based Next-Generation Sequencing Analysis. J Mol Diag 17(6):809-809, 2015. e-Pub 2015.
26. Shaw KR, Zeng J, Bailey AM, Johnson A, Litzenburger B, Holla V, Bernstam EV, Mills GB, Mendelsohn J, Routbort M, Meric-Bernstam F. Development of a public knowledgebase to facilitate decision support for clinical cancer genomics reporting and clinical trial enrollment. J Clin Oncol(Abstract e22163), 2015. e-Pub 2015.
27. Meric-Bernstam F, Brusco L, Daniels MS, Strong LC, Shaw KR, Lu KH, Qi Y, Lara-Guerra H, Litton JK, Zhao H, Eterovic AK, Arun B, Routbort M, Janku F, Davies MA, Kopetz S, Mendelsohn J, Mills GB, Chen K. Prevalence of incidental actionable germline mutations in 1,000 advanced cancer patients on a prospective somatic genomic profiling program. J Clin Oncol(Abstract 1510), 2015. e-Pub 2015.
28. Oba J, Wang W, Eterovic AK, Stephan CC, Roszik J, Kale CR, Haymaker CL, Routbort M, Haydu LE, Bernatchez C, Davies MA, Lazar AJF, Grimm EA, Woodman SE. A global genomic and small molecule inhibitor interrogation of KIT mutant melanoma to reveal underlying biology and novel molecular targets. J Clin Oncol(Abstract 9039), 2015. e-Pub 2015.
29. Singh C, Routbort M, Broaddus R. CTNNB1 mutations in advanced stage and/or recurrent endometrial endometrioid adenocarcinoma. Mod Pathol 28(Supplement 2):307A, 2015. e-Pub 2015.
30. Ok CY, Salim A, Loghavi S, Luthra R, Routbort M, Singh R, Zuo Z, Pierce S, Garcia-Manero G, Kantarjian H, Cortes J, Ravandi F, Andreef M, Medeiros LJ, Patel K. DNMT3A mutation as a molecular marker for monitoring minimal residual disease in acute myeloid leukemia. Mod Pathol 28(Supplement 2):370A, 2015. e-Pub 2015.
31. Broaddus R, Litzenburger B, Shaw K, Lee JJ, Kinyua W, Sajan B, Routbort M, Patel K, Luthra R, Singh R, Kopetz S. Two-staged approach in identifying therapeutic targets for patients with advanced cancers. Mod Pathol 28(Supplement 2):454A, 2015. e-Pub 2015.
32. Loghavi S, Broaddus R, Daniels M, Meric-Bernstam F, Kopetz S, Chen K, Strong L, Almohammedsalim A, Ok CY, Brusco L, Kopetz S, Lu K, Lee J, Medeiros LJ, Singh R, Patel K, Luthra R, Routbort M. Dealing with the incidental: Experiences implementing the ACMG guidelines for reporting germline findings in a comprehensive somatic mutation assay. Mod Pathol 28(Supplement 2):460A, 2015. e-Pub 2015.
33. Goswami R, Chen H, Patel K, Routbort M, Yao H, Dang H, Barkoh B, Aldape K, Chowdhuri SR, Stewart J, Medeiros L, Broaddus R, Singh R, Luthra R. Improving next-generation sequencing (NGS) success in solid tumors. Mod Pathol 28(Supplement 2):499A, 2015. e-Pub 2015.
34. Jabbar K, Routbort M, Singh C, Rashid A, Broaddus R. Impact of tumor necrosis on success of clinical next generation sequencing. Mod Pathol 28(Supplement 2):501A, 2015. e-Pub 2015.
35. Chen H, Singh R, Huo L, Lu XY, Bousamra A, Abraham R, Mehrotra M, Mishra BM, Virani S, Chowdhuri SR, Routbort M, Aldape K, Broaddus R, Sahin A, Patel K, Luthra R. FGFR1 and EGFR amplification in breast cancer. Mod Pathol 28(Supplement 2):38A, 2015. e-Pub 2015.
36. Chowdhuri SR, Goswami R, Chen H, Barkoh B, Manekia J, Patel K, Routbort M, Singh R, Broaddus R, Medeiros LJ, Staerkel G, Luthra R, Stewart J. Factors affecting the success of next-generation sequencing in cytology specimens. Mod Pathol 28(Supplement 2):105A, 2015. e-Pub 2015.
37. Tetzlaff M, Pattanaprichakul P, Wargo J, Fox P, Patel K, Estrella J, Broaddus R, Davies M, Routbort M, Lazar A, Prieto V, Hwu WJ, Gershenwald J, Woodman S, Torres-Cabala C, Curry J. Pattern as a surrogate of BRAFV600 mutation status in 154 patients with advanced stage melanoma. Mod Pathol 28(Supplement 2):126A, 2015. e-Pub 2015.
38. Singh C, Routbort M, Broaddus R. Targeted next generation sequencing (NGS) for the identification of clinically actionable mutations in advanced stage/recurrent endometrial carcinoma (EC). Mod Pathol 28(Supplement 2):307A, 2015. e-Pub 2015.
39. Chen H, Luthra R, Routbort M, Patel K, Singh R, Dang H, Barkoh B, Cabanillas M, Aldape K, Broaddus R, Williams M. Mutation profile of advanced thyroid carcinomas by next-generation sequencing: The MDACC experience. Mod Pathol 28(Supplement 2):322A, 2015. e-Pub 2015.
40. Kanagal-Shamanna R, Bueso-Ramos C, Singh R, Routbort M, Miranda R, Lu G, Ravandi F, Dinardo C, Kantarjian H, Medeiros LJ, Patel K, Luthra R. Next-generation sequencing of sporadic acute myeloid leukemia demonstrates GATA2 mutation to be a secondary event frequently associated with other driver mutations. Mod Pathol 28(Supplement 2):354A, 2015. e-Pub 2015.
41. Loghavi S, Kanagal-Shamanna R, Ok CY, Almohammedsalim A, Bueso-Ramos C, Routbort M, Mehrotra M, Verstovsek S, Kantarjian H, Medeiros LJ, Luthra R, Patel K. Myeloproliferative neoplasms with calreticulin mutations exhibit distinctive megakaryocytic features and increased vasculr proliferation. Mod Pathol 28(Supplement 2):361A, 2015. e-Pub 2015.
42. Kopetz S, Overman MJ, Chen K, Lucio-Eterovic AK, Kee BK, Fogelman DR, Dasari A, Raghav KPS, Sanchez EV, Phillips J, Shureiqi I, Garrett CR, Wolff RA, Patel K, Aldape KD, Luthra R, Routbort M, Maru DM, Meric-Bernstam F, Eng C. Mutation and copy number discordance in primary versus metastatic colorectal cancer (mCRC). J Clin Oncol(Abstract 3509), 2014. e-Pub 2014.
43. Takahashi K, Kantarjian HM, Garcia-Manero G, Stevens RJ, Dinardo CD, Allen J, Hardeman E, Carrier S, Powers C, Keane P, Pierce S, Routbort M, Nguyen T, Smith B, Frey J, Perry K, Frenzel JC, High R, Futreal A, Chin L. MD Anderson’s Oncology Expert Advisor powered by IBM Watson: A Web-based cognitive clinical decision support tool. J Clin Oncol(Abstract 6506), 2014. e-Pub 2014.
44. Boland GM, Piha-Paul SA, Subbiah V, Brusco L, Herbrich SM, Baggerly KA, Routbort M, Patel K, Luthra R, Naing A, Fu S, Falchook GS, Hong DS, Wheler JJ, Janku F, Shaw KR, Aldape KD, Mendelsohn J, Mills GB, Meric-Bernstam F. Clinical next-generation sequencing to identify actionable alterations in a phase I program. J Clin Oncol(Abstract 11115), 2014. e-Pub 2014.
45. Kim DW, Nowroozi S, Kim K, Davies MA, Routbort M, Lazar AJF, Frankian S, Siroy A, Bedikian AY, Papadopoulos NE, Hwu W, Hwu P, Woodman S, Patel SP, Kim K. Clinical characteristics of patients with non-V600 BRAF mutant melanomas. J Clin Oncol(Abstract 9100), 2014. e-Pub 2014.
46. Priyanka P, Sinha A, Khoury J, Patel K, Routbort M, Singh R, Luthra R, Pemmaraju N, Takahashi K, Muzzafar T. Chronic myelomonocytic leukemia: Next-generation sequencing in 30 treatment-naive cases. J Clin Oncol(Abstract 7051), 2014. e-Pub 2014.
47. Siroy AE, Prieto VG, Gershenwald JE, Woodman SE, Roszik J, Aldape KD, Luthra R, Patel KP, Routbort MJ, Davies MA, Lazar AJ. Clinical Next Generation Sequencing Reveals Divergent Mutation Patterns in BRAF V500, BRAF Non-V600, and NRAS Mutations in Advanced Melanoma. Modern Pathology 27 Supp 2:143A, 2014. e-Pub 2014.
48. Jabbar KJ, Patel K, Aldape K, Broaddus R, Shaw K, Meric-Bernstam F, Chowdhuri S, Lazar A, Goswami R, Medeiros LJ, Luthra R, Routbort MJ. Gene Amplification Patterns Identified By Next Generation Sequencing in a Large Tumor Cohort. Modern Pathology 27(Supplement 2):462-3A, 2014. e-Pub 2014.
49. Goswami R, Ok C, Patel K, Wang S, Routbort M, Manekia J, Jabbar KJ, Barkho B, Medeiros LJ, Singh R, Luthra R. Novel Mutations in Therapy-Related and De Novo Myelodysplasia: Results from a Next-Generation Sequencing Pilot Study. Modern Pathology 27(Supplement 2):461A, 2014. e-Pub 2014.
50. Ok CY, Kanagal-Shamanna R, Singh R, Aldape KD, Patel KP, Routbort M, Luthra R, Medeiros LJ, Wang SA. Multigene Mutation Analysis Using Next Generation Sequencing in AML and MDS. Modern Pathology 27(Supplement 2):367A, 2014. e-Pub 2014.
51. Salim AA, Wang WL, Aldape KD, Luthra R, Routbort M, Lazar A. Clinical Next Generation Sequencing of Sarcomas: Initial experience of 133 Cases. Modern Pathology 27(Supplement 2):27A, 2014. e-Pub 2014.
52. Chowdhuri S, Routbort M, Singh R, Aldape K, Broaddus R, Lazar A, Medeiros LJ, Barkho B, Reddy N, Luthra R, Patel KP. The Art and Science of Next Generation Sequencing Data Interpretation: Value of Pattern Recognition and Statistical Analysis in Distinguishing True Mutations from Artifacts. Modern Pathology 27(Supplement 2):530A, 2014. e-Pub 2014.
53. Chowdhuri SR, Routbort M, Patel K, Singh R, Broaddus R, Lazar A, Sahin A, Mills G, Mendelsohn J, Meric-Bernstam F, Aldape K, Luthra R. Multi-gene Mutational Profiling of Breast Carcinoma using Next Generation Sequencing. Modern Pathology 27(Supplement 2):530A, 2014. e-Pub 2014.
54. Loghavi S, Zuo Z, Zhang L, Stingo F, Patel KP, Singh RR, Luthra R, Routbort MJ, Medeiros J, Cortes JE, Ravandi-Kashani F, Kantarjian HM, Khoury JD. De Novo Acute Myeloid Leukemia with DNMT3A, FLT3, and NPM1 Mutations. Modern Pathology 27(Supplement 2):359A, 2014. e-Pub 2014.
55. Portier BP, Patel K, Medeiros LJ, Singh R, Aldape KJ, Hamilton S, Luthra R, Routbort M. Identification of HER-2/neu amplification using amplicon based benchtop next generation sequencing. San Antonio Breast Cancer Symposium, 2013. e-Pub 2013.
56. Nowroozi S, Zuo Z, Patel K, Patel SP, Luthra R, Routbort M, Lazar AJF, Davies MA, Hasanein H, Papadopoulos NE, Hwu WJ, Bedikian AY, Woodman S, Hwu P, Kim K. Clinical characteristics of melanoma patients with non-V600E/K BRAF mutations. J Clin Oncol 31(15):Supplement S, 2013. e-Pub 2013.
57. Portier BP, Patel KP, Singh R, Routbort M, Handal B, Barkoh BA, Reddy N, Lazar A, Davies M, Medeiros L, Aldape K, Luthra AR. Next Generation Sequencing of a Large Cohort of Solid Tumors Reveals IDH1 Mutations Present in Melanoma at a Higher Frequency than Expected. United States and Canadian Assoc Pathology Annual 2013, 2013. e-Pub 2013.
58. Zhang L, Aladily T, Chakhachiro Z, Yao H, Su X, Routbort M, Wang S, Luthra R, Miranda R, Medeiros L, Bueso-Ramos C, Khoury JD. RAS Mutation Is a Poor Prognostic Factor in Patients with Chronic Myelomonocytic Leukemia. United States and Canadian Assoc Pathology Annual 2013, 2013. e-Pub 2013.
59. Portier BP, Luthra R, Singh R, Routbort M, Handal B, Reddy N, Barkoh B, Zuo Z, Medeiros J, Aldape K, Patel K. Quantitative Assessment of Mutant Allele Burden in Solid Tumors by Semiconductor Based Multi-Gene Next Generation Sequencing. United States and Canadian Assoc Pathology Annual 2013, 2013. e-Pub 2013.
60. Reddy NG, Singh R, Patel KP, Grant F, Rahimi H, Harmon MA, Handal B, Barkoh BA, Routbort M, Aldape KD, Medeiros JL, Luthra R. Does Formalin-Fixation and Paraffin-Embedding Affect Genotyping by Next Generation Sequencing?. Journal Molec Diag 14(6):738, 2012. e-Pub 2012.
61. Singh RR, Reddy NG, Barkoh B, Handal B, Patel KP, Routbort M, Aldape KD, Medeiros JL, Luthra R. Clinical Validation of a 46 Cancer Gene Mutation Panel using SemiConductor Based Next-Generation Sequencing Technology. Journal Molec Diag 14(6):725, 2012. e-Pub 2012.
62. Kanagal-Shamanna R, Singh RR, Routbort MJ, Aldape KD, Handal B, Rahimi H, Reddy NG, Barkoh BA, Mishra B, Paladugu AV, Manekia J, Staerkel GA, Medeiros L, Luthra R, Patel KP. Application of Next-Generation Sequencing in Using Fine Needle Aspiration Smears and Cell Blocks from Solid Tumors. Journal Molec Diag 14(6):705, 2012. e-Pub 2012.
63. Patel KP, Singh R, Reddy N, Routbort M, Aldape K, Medeiros L, Sargent R, Chen SS, Yin C, Zuo J, Barkoh BA, Handal B, Paladugu A, Patel R, Rahimi H, Grant F, Luthra R. Comparison of Next Generation Sequencing Platforms for Multi-Gene Mutational Profiling of Hematologic Malignancies in a Clinical Diagnostics Laboratory. Journal Molec Diag 14(6):660, 2012. e-Pub 2012.
64. Routbort M, Handal B, Patel KP, Singh R, Aldape K, Reddy N, Barkoh B, Riben M, Medeiros L, Luthra R. OncoSeek - A Versatile Annotation and Reporting System for Next Generation Sequencing-Based Clinical Mutation Analysis of Cancer Specimens. Journal Molec Diag 14(6):747, 2012. e-Pub 2012.
65. Hwang J, Fisch M, Zhang H, Kallen M, Routbort M, Lal LS, Vierling J, Suarez-Almazor M. Reactivation of hepatitis B infection among patients with cancer. J Clin Oncol 54(Supplement 1):445A-445A, 2011. e-Pub 2011.
66. Middleton L, Puig P, Hamilton S, Routbort M, Luthra R, Rashid A, Reynolds A, Heydon L, Dunn J, Hiumin L, Jackson S, Guerreo J, Lewing C, Bowman C, Ponder J, Cook P, Phipps R, Acosta C, Johnson-Hamilton M, Ngoc HL, Woods J. Pre-analytic Process Improvements for Molecular Testing improves Turn Around time for Results. University of Texas System Clinical Safety and Effectiveness Conference. e-Pub 2011.
67. Hwang J, Fisch M, Zhang H, Kallen MA, Routbort M, Lal L, Vierling J, Suarez-Almazor M. Predictors of hepatitis B screening among patients with cancer. J Clin Oncol 29(4), 2011. e-Pub 2011.
68. Riben M, Nesbitt L, Ninan S, Routbort MJ. Patient safety initiatives at the grossing bench: design, implementation, and experience with bar-code driven specimen-block reconciliation for biopsy grossing. Pathology Informatics 2010, 2010. e-Pub 2010.
69. Routbort MJ, Ninan S, Riben M. Optimizing access to digital pathology slides: overcoming User interface limitations and the case-centric paradigm. Pathology Informatics 2010, 2010. e-Pub 2010.
70. Routbort MJ, Ninan S, Riben M. Integration of Digital Pathology Systems: A Software Development Approach. Pathology Informatics 2010, 2010. e-Pub 2010.
71. Hwang JP, Fisch MJ, Zhang H, Routbort MJ, Lal LS, Vierling JM, Suarez-Almazor M. Hepatitis B screening and positivity prior to chemotherapy. J Clin Oncol 28:15s, 2010 28(15s):abs 9008, 2010. e-Pub 2010.
72. Routbort MJ, Ninan S, Nesbitt L, Riben M. Implementing rapid real-time process defect collection to optimize anatomic pathology workflow: a two-pronged approach based on end-user work setting. Advancing Practice, Instruction and Innovation through Informatics, 2008. e-Pub 2008.
73. Routbort MJ, Riben M. A state pattern recognition and extraction engine tool for legacy system interoperability. Advancing Practice, Instruction and Innovation through Informatics, 2007. e-Pub 2007.
74. Routbort MJ, Riben M. SQL Comparator: An open source tool for minimal change database validation. Advancing Practice, Instruction and Innovation through Informatics, 2007. e-Pub 2007.
75. Riben M, Routbort MJ, Nesbitt L. Adapting IT change management methods for informatics driven process improvement in the laboratory: Developing a framework for the 4-E change management strategy. Advancing Practice, Instruction and Innovation through Informatics, 2007. e-Pub 2007.
76. Ren Y, Leventaki V, Routbort MJ, Jones D, Medeiros J, Bueso-Ramos C. Abnormal cytoplasmic localization of ARF in acute myeloid leukemia with NPM gene mutations. American Society for Hematology Annual Meeting, 2006. e-Pub 2006.
77. Warrington JS, Routbort MJ, Buckley PJ, Gong JZ, Goodman BK, Lagoo AS. Significance of cytogenetic and immunophenotypic findings in patients with acute myeloid leukemia arising from myelodysplastic syndrome. USCAP Abstr, 2006. e-Pub 2006.
78. Routbort MJ, Grim E, Schmidt R. Optimized document management in anatomic pathology: two paths to a common workflow with analysis of benefits. Advancing Practice, Instruction and Innovation through Informatics, 2006. e-Pub 2006.
79. Riben M, Routbort MJ. The 4-E change management strategy for implementing pathology workflow software: entice, engage, enlist, and enjoy. Advancing Practice, Instruction and Innovation through Informatics, 2006. e-Pub 2006.
80. Riben M, Routbort MJ, Andrechak G. RFID tag design for the pathology laboratory. Advancing Practice, Instruction and Innovation through Informatics, 2006. e-Pub 2006.
81. Routbort MJ, Mussani S, Riben M. PathStation: A pathology workflow integration engine using an enterprise application mash-up design pattern. Advancing Practice, Instruction and Innovation through Informatics, 2006. e-Pub 2006.
82. Routbort MJ, Fleming J, Elliot T, Dave S, Thomas M, Price C, Riben M. SPiDR: A shared pathology data repository using a service-oriented architecture for mission critical lab results delivery. Advancing Practice, Instruction and Innovation through Informatics, 2006. e-Pub 2006.
83. Routbort MJ, Riben M. Introducing new technology into and old grossing facility: hands-free computing to facilitate grossing workflow. Advancing Practice, Instruction and Innovation through Informatics, 2006. e-Pub 2006.
84. Routbort MJ, Riben M. Out of the LIS and into the EMR: Taking control of the function display of anatomic pathology data. Advancing Practice, Instruction and Innovation through Informatics (APIII), 2005. e-Pub 2005.
85. Chen W, Rassidakis G, Routbort MJ, Jones D, Medeiros J, Bueso-Ramos C. A biologically distinctive subgroup of acute myelogenous leukemia with characteristic nucelar morphology and a high frequency of FLT3 mutation. American Society for Hematology Annual Meeting, 2005. e-Pub 2005.
86. Habra MA, Rodriguz MA, Routbort MJ, Holsinger FC, Perrier ND, Waguespack SG. Primary natural killer/T Cell lymphoma of the adrenal gland: a unique presentation of a rare disorder. Endo Soc Abstr, 2005. e-Pub 2005.
87. Gong JZ, Bayerl MG, Sandhaus LM, Sebastian S, Lagoo AS, Chiu J, Comito M, Szabolcs P, Routbort M, Buckley PJ. Post-transplant lymphoproliferative disorder after umbilical cord blood transplantation in children: A study of 6 cases. USCAP Abstr, 2005. e-Pub 2005.
88. Routbort MJ, JFMadden. A Web-based, database-driven SNOMED CT-enabled structured template system for implementation of the CAP cancer protocols. CAP Annual Meeting, San Diego, 2003. e-Pub 2003.
89. Routbort MJ, Horvatinovich J, Buckley P, Lagoo AL. An open-source software system for creation, distribution, and management of paperless flow cytometry reports. 18th Annual Clinical Cytometry Meeting, Arlington, 2003. e-Pub 2003.
90. Routbort MJ, JFMadden. CAP cancer templates in practice: A user-friendly software system for cancer report entry, transmission and automated SNOMED encoding. Advancing Practice, Instruction and Innovation through Informatics (APIII), Pittsburgh, 2003. e-Pub 2003.
91. McCall SM, Datto MB, Routbort MJ. Quantitative Analysis of the Hybrid Capture®II Human Papillomavirus Assay. USCAP Abstr, 2003. e-Pub 2003.
92. Datto MB, Routbort MJ, Vollmer RT. An independent analysis of the ovarian cancer proteome. USCAP Abstr, 2003. e-Pub 2003.
93. Holt J, Routbort MJ. Implementation of a pathology slide teaching database. Advancing Pathology Informatics, Imaging, and the Internet. Arch. Path. Lab. Med 127(7):799, 2002. e-Pub 2002.
94. Routbort MJ. Implementation of web tools for pathology education, resource management, and document collaboration Advancing Pathology Informatics, Imaging, and the Internet. Arch. Path. Lab. Med 127(7):802, 2002. e-Pub 2002.
95. Routbort MJ, Reimer KA, Blumrick R, Hulette CM. Myocardial infarction in a fetus with Kell alloimmunization and hemolytic disease. USCAP Abstr, 2001. e-Pub 2001.
96. Routbort MJ, AProia. Building a bridge: From a legacy system to a modern relational database. Advancing Pathology Informatics, Imaging, and the Internet. Arch. Path. Lab. Med 126(7):788-9, 2001. e-Pub 2001.

Book Chapters

1. Spinosa JC, Arnaout R, Berman MA, Birdsong G, Boguski MS, Booker D, Carter A, Castellani W, Chen D, Chen P, Dash RC, de Baca M, Elevitch F, Gilbertson J, Harrison J, Henricks W, Kennedy M, Knapik C, Olson JE, Robb J, Routbort M, Rudolf JW, Simpson RW, Sinard J, Wilkerson M. Clinical Informatics. In: CAP Pathology Resource Guide. College of American Pathologists, 2016.
2. Routbort MJ. Networks and Workstations. In: Pathology Informatics: Theory and Practice. ASCP Press, 2012.
3. Routbort MJ, McNamara JO. Excitatory amino acids and use-dependent plasticity: epileptogenesis. In: Excitatory amino acids and the cerebral cortex. MIT Press, 313-23, 1996.

Letters to the Editor

1. Jelloul, FZ, Routbort, MJ, DiNardo, C, Bueso-Ramos, CE, Kanagal Shamanna, R, Thakral, B, Zuo, Z, Yin, CC, Loghavi, S, Ok, CY, Wang, SA, Tang, Z, You, MJ, Patel, KP, Medeiros, LJ, Quesada, AE. DDX41 mutations in patients with non-myeloid hematologic neoplasms. American journal of hematology 98: E193-E196, 2023.